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1.Introduction 
1.1 Principles of antigen specific immunotherapy of tumors 
 
     A thorough understanding of the immuno-regulatory pathways supporting or 
suppressing the generation of CD8+ CTL is of utmost relevance for the 
implementation of immunotherapeutic approaches against tumors for several 
reasons: (i) CD8+ T cells are presumably the most important effector cells for 
immunotherapeutic approaches against cancer; (ii) endogenous as well as vaccine-
driven immune responses of CD8+ T cells against tumor-specific antigens are often 
rather weak, such that they can be measured only after several rounds of 
restimulation in vitro (Muul et al. 1987), (iii) tumor patients often suffer from 
immunosuppressive effects directly and indirectly caused by the tumor. If it were 
possible to counteract adverse immunoregulatory effects and to promote 
endogenous immunostimulatory mechanisms in tumor patients, the use of tumor-
specific CD8+ CTL could be established as a potent additional modality in tumor 
therapy.  
Massive clonal expansion and acquisition of effector functions of CD8+ T cells 
requires induction by fully matured DC which are able to provide to naïve CD8+ T 
cells beyond the inductive signals 1 and 2 an additional signal 3 (reviewed in 
Mescher et al.). So far, as signal 3 the cytokines IL-12 and type I interferons (IFN) 
have been identified. DC can be induced to secrete these cytokines in either an 
antigen-specific or a non-specific fashion. Antigen-specific “licensing” of DC to 
produce IL-12 can be achieved by ligation of CD40 on DC by CD40L (CD154) on 
CD4+ T helper cells. As a consequence of this insight, a recent improvement in 
tumor-specific vaccination was to mix MHC class II-restricted peptides with MHC 
class I-restricted peptides so that specific CD4+ T helper cells are induced in parallel 
to CD8+ T cells. The strength and quality of the CD8+ T cell response was further 
improved by linking MHC class I- and II-restricted epitopes so that processing and 
presentation of both epitopes by the same antigen-presenting cell (APC) was 
warranted.  
Despite these improvements, even T cell responses against definitely foreign, virus-
derived tumor-associated antigens were mostly too weak or short-lived to achieve 
control of tumor cells. One approach to  strengthen the antigen-specific CD 8+ CTL is 
to optimize the quality of the CD4+ T helper response, e.g. by enhancing their Th1 
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and suppressing their Th2 activities (Pardoll et al., 2002; Rosenberg et al., 2008; 
Figdor et al., 2004). 
But even antigen-specific, fully competent effector CD8+ CTL induced by fully 
inflammation-matured DC did not necessarily achieve effective control of tumor cells, 
because these CTL accumulated largely in the lymph nodes draining the vaccination 
site instead of patrolling through the systemic circulation (van der Burg et al., 2006; 
Welters et al., 2007). Finally, even if antigen-specific effector CD8+ CTL might 
infiltrate the tumor tissue, they can be blocked or inactivated by tumor cells via 
various mechanisms (Blattman and Greenberg, 2004; Melief, 2008). One of the most 
recently discovered is the expression of specific inhibitors of cytotoxic effector 
molecules (Abdullah et al., 2007; Bots et al., 2005). 
 
 
1.2. Expression of specific inhibitors of cytotoxic effector molecules in tumor    
      cells  
 
     Cells of various murine tumor types express the serine protease inhibitor 6 (SPI-
6), the specific inhibitor of granzyme B (grzB). Serpin PI-9, the human homolog of 
SPI-6,  was previously shown to be expressed by dendritic cells, which prevents 
premature destruction of these professional antigen-presenting cells (APC), and by 
cells at immune-privileged sites, where degranulation of CTL is potentially deleterious 
(Bladergroen et al., 2001; Medema et al., 2001). In addition, murine SPI-6 was 
reported to play a crucial role in the protection of CTL against the suicidal effects of 
their own grzB (Zhang et al., 2006). Expression of the human serpin PI-9 and its 
murine homologue SPI-6 has been detected in various types of melanoma, 
carcinomas, and lymphomas (David-Watine et al., 1987; Medema et al., 2001; Bots 
etal., 2005) and was realized to be linked with the escape of tumor cells from 
immunosurveillance. 
 
     Altogether, the experiences acquired in tumor immunology  within the previous 
two decades indicate that an improved understanding of the function and regulation 
of T cells within the microenvironment during induction, homing and execution of 
effector functions is a prerequisite for establishing protocols for reliable and sustained 
control of tumors by the immune system.  
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1.3. The experimental system to study immuno-regulatory mechanisms 
 
     To understand immunoregulatory mechanisms in weak tumor-specific immune 
responses, we study the simian virus 40 (SV40) large tumor antigen (TAg)-specific 
rejection of syngeneic TAg-expressing mKSA tumor cells in BALB/c mice (J. Zerrahn 
et al., 1996; Utermöhlen et al., 2001) The mKSA cells form in syngeneic mice 
fibrosarcomas after s.c. injection and produce severe peritoneal carcinosis after i.p. 
inoculation. We chose this murine tumor model because it exhibits features 
resembling the clinical situation with regard to the extremely weak reactivity of the 
immune system towards tumor-specific antigens. With respect to the generation of 
TAg-specific CD8+ CTL, BALB/c mice were characterized in the literature as low- or 
even non-responders (Bright et al., 1996;  Gooding et al.,1977; Knowles et al., 1997; 
Newmaster et al., 1998, Schirmbeck et al., 1996; Tevethia et al., 1990, Pfizenmaier 
et al., 1980)  This is nicely documented by the fact that so far only a single 
subdominant H-2Kd-restricted epitope of TAg was identified after several rounds of 
restimulation in vitro of T cells from SV40-immune BALB/c mice (Newmaster et al., 
1998), while in C57BL/6 mice, known to mount a strong CTL response against TAg, 
five immunodominant MHC class-I-restricted epitopes have been identified (Tevethia 
el., 1990).  
However, our group detected a small but highly cytotoxic population of TAg-specific 
CD8+ CTL among the peritoneal exudate cells of TAg-immune BALB/c mice 
challenged i.p. with TAg-expressing mKSA tumor cells (Baschuk et al., 2007). These 
TAg-specific CTL depend on the support of CD4+ T helper cells over the whole 
course of tumor cell rejection (Utermöhlen et al., 2001). In TAg-immunized BALB/c 
mice challenged with mKSA cells, CD4+ tumor-associated lymphocytes (TAL) secrete 
both typical Th1 cytokines as IFN-γ and IL-2 and typical Th2 cytokines, e.g. IL-4 and 
IL-10, over the whole course of tumor rejection.    
 
 
1.4. Effects of IL-4 on CD8+ CTL 
 
    Interleukin-4 (IL-4) is a prototypic type 2 T helper (Th2) cytokine. Its major effects 
are to promote differentiation of Th2 cells, thereby supporting humoral immune 
responses. Moreover, IL-4 is a strong antagonist of Th1 cells and thus of cellular 
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immune responses (Seder et al.,1994). Despite these clearly defined functions of IL-
4, the effects of this cytokine upon antigen specific CTL are still ambiguous, because 
IL-4 has been reported to either promote or inhibit the generation of antigen-specific 
CD8+ cytotoxic T cells in different systems (Utermöhlen et al., 2001; J. Zerrahn et al., 
1996, Miller et al., 1990; Erard et al., 1993; M. Croft et al., 1994; Noble et al., 1995; 
Moran et al., 1996; Aleman et al., 2002; Bright et al 1996; Gooding et al., 1977; 
Knowles et al., 1979; N. Kienzle et al 2002, 2005; Schuler et al., 2001, 1999). The 
most prominent example of unpredicted effects of IL-4 on CTL was reported by 
Jackson et al. who generated an ectromelia virus encoding murine IL-4 (Jackson et 
al., 2001). This IL-4-expressing virus caused acute mousepox accompanied by high 
mortality even in mouse strains which are resistant to wild type ectromelia virus. The 
massive increase in pathogenicity was found to be due to suppression of the CTL 
response by IL-4. Less dramatic suppressive effects of IL-4 upon CTL function during 
infection were observed in other systems when mice were treated either with 
exogenous IL-4 or with recombinant vaccinia virus expressing IL-4 (Aung et al., 
2000). Mice treated with mAb neutralizing IL-4 during immunization mounted an 
enhanced CTL response following challenge with RSV (Tang et al., 1994). During 
Sendai virus infection IL-4 deficient (IL-4-/-) mice showed a potent response of 
cytotoxic T lymphocyte (CTL)  recovered by bronchoalveolar lavage, while in the 
same animals the prevalence of virus-specific CTL precursors was consistently 
diminished in the spleen and in regional lymph nodes (Mo et al., 1997). On the other 
hand, no alterations in T cell activation or virus clearance could be detected in IL-4-/- 
mice during infection with vaccinia virus or Lymphocytic Choriomeningitis (LCM) virus 
(Bachmann et al., 1995). Additionally puzzling was the observation that IL-4 can act 
as a growth factor for CD8+ T cells in vitro ( Miller et al., 1990; Noble et al., 1990)]. 
 
 
1.5. Effects of IL-10 on CD8+ CTL 
 
     IL-10 is of outstanding interest with regard to the modulation of CD8+ CTL, 
because this cytokine acts in many different systems as an inhibitor of cellular 
immune responses, but it has also been reported to be a maturation factor for CTL in 
other systems (Chen et al., 1991; Wang et al., 1994; Goillot et al., 1994; Giovarelli et 
al.,1995; Sharma et al., 1999; Santin et al., 2000; Fujii et al., 2001). 
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Interleukin 10 (IL-10) acts strongly anti-inflammatory on cells of both the innate and 
the acquired immune system. It is secreted not only by various cell types of the 
innate and adaptive immune system but also by keratinocytes and intestinal epithelial 
cells (for review (Moore et al., 2001)). This puts IL-10 as a major player into the 
highly complex regulatory networks of immune responses. The most important 
function of IL-10 seems to be the inhibition of the production of pro-inflammatory 
cytokines by macrophages and dendritic cells. Thereby IL-10 acts at the interface 
between innate and adaptive immune responses as a regulator suppressing or down-
modulating immune responses to microorganisms. This is most prominently proven 
by the phenotype of IL-10 deficient mice: IL-10-/- mice develop severe 
immunopathology in response to colonization of their intestines by the physiologic gut 
microflora. Conventionally housed IL-10-/- mice develop chronic enterocolitis within 
the entire intestinal tract, with the duodenum, proximal jejunum, and proximal colon 
being most severely affected by mucosal inflammation with extensive 
lymphoplasmocytic and histiocytic infiltration of the lamina propria (Kuhn et al., 1993). 
IL-10-/- mice kept under specific pathogen free (SPF) conditions lack inflammatory 
alterations in the small intestine and show lesions mainly in the proximal colon which 
are less severe than in conventionally housed mice (Kuhn et al., 1993). These data 
suggest that the inflammatory disease is triggered by enteric microorganisms. 
Importantly, IL-10-/- mice do not show spontaneous lymphoproliferative or 
inflammatory activity without contact to microorganisms or their products, as 
observed for example in FoxP3-deficient mice lacking regulatory T cells (Treg) 
(Fontenot et al., 2003). Thus, IL-10 is a main factor that fine tunes the delicate 
balance between sufficiently effective immune responses against microorganisms 
and immunopathologic damage of host tissues. 
On T lymphocytes, IL-10 can act in at least two fashions: In an indirect mode, IL-10 
inhibits in immature DC the expression of costimulatory and MHC class II molecules. 
The resulting lack of inflammatory DC may inhibit Th1 inflammatory responses or 
even end in the induction of anergy in T cells. In a direct mode, IL-10 can inhibit 
production of cytokines and chemokines as well as chemotaxis of T lymphocytes. 
However, even some stimulatory effects of IL-10 on T cells have been described 
(Groux et al., 1998; Santin et al., 2000), so that the net effect of IL-10 or of IL-10 
inhibition cannot easily be predicted in a given immunologic situation. 
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1.6. The experimental system to study the effects of inhibitors of cytotoxic      
        effector molecules  
 
     Target cell resistance against CTL or NK cell mediated cytotoxicity of embryonic 
stem ES cell-derived teratomas is of particular interest for several reasons: For 
example, ES cell derived teratomas can be viewed as a model for the cancer stem 
cell hypothesis which became accepted for a growing list of tumors over the last few 
years (Andrews, et al. 2005). Thus, a stem cell-dependent tumor-model appears 
more physiologic than a model relying on a virus-transformed tumor cell line. 
Teratomas are tumors that comprise disorganized tissue derived from all three 
embryonic germ layers. Undifferentiated ES cells were reported to form teratomas 
not only in immuno-defficient mice, but also in immunocompetent syngeneic and in 
immunocompetent allogeneic recipients (Koch, et al. 2008).  
While transplants of undifferentiated ES cells will probably not be used for therapeutic 
purposes, a few contaminating undifferentiated ES cells in transplants of more 
differentiated ES cell-derivatives cannot be neglected, because as few as two ES 
cells (Lawrenz et al., 2004) can give rise to teratomas. Cancer stem cells are defined 
by the capacity for self-renewal (Thomson et al., 1998; Evans et al., 1981) and the 
potential to differentiate into any cell type of the specific tumor-type. Cancer stem 
cells are supposed to persist in tumors and survive conventional tumor therapy, 
giving rise to relapsing tumors. Therefore, development of specific therapies targeted 
at cancer stem cells may eradicate the truly tumorigenic cell type, preventing relapse. 
We also resorted to this system, because our group already detected the expression 
of cathepsin B, the specific inhibitor of perforin, and SPI-6, the specific inhibitor of 
granzym B, in ES cells, and characterized the effects of these inhibitors in the 
interaction of ES cells and CTL in vitro (Abdullah et al., 2007). In the present study 
the interaction of ES cells with NK cells, i.e. the innate cytotoxic effector cells type, in 
vitro and in vivo, was analysed. A better understanding of NK cell interactions with 
tumors, recently attracted fast growing interest for several reasons. The most obvious 
explanations are: (i) Use of NK cells against tumor cells does not require 
identification of tumor-specific antigens, or antigen-specific immunization. (ii) Being 
triggered by recognition of cells with low surface expression of MHC class I 
molecules, NK cells might become the therapeutic approach to eliminate tumor cells 
that lost MHC class I due to selective pressure of antigen-specific CTL therapy. 
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ES cells are known to express none or low levels of MHC class I molecules on their 
surface (Drukker et al., 2002, 2006; Bonde et al., 2006; Abdullah et al., 2007). 
According to the “missing self hypothesis“ of NK cell activation (Ljunggren et al., 
1990) ES cells should be ideal targets for NK cells. However, human (Drukker et al., 
2002, 2006) or murine ES cells (Bonde et al., 2006) were reported to be poorly lysed 
by NK cells in vitro. Our group recently reported that ES cells, despite being fully 
recognized, are not susceptible to cytolysis by CD8+ CTL. Having revealed that ES 
cells express high levels of cathepsin B and SPI-6, the specific endogenous inhibitors 
of the cytotoxic effector molecules perforin and granzyme B, respectively, protecting 
them against lysis by CD8+ CTL. 
This project aimed at revealing the involvement of SPI-6 and cathepsin B in the low 
susceptibility of ES cells to NK cells. 
 
 
1.7. Objective 
 
     The aim of this project was to elucidate different approaches to enhance the 
effectiveness of tumor-specific immune responses and to further characterize 
molecular and translational aspects of cytotoxic effector : target cell interactions 
concerning the immune surveillance of cancer. 
 
 7
                                                                                                    Material and Methods  
2. Materials and Methods I 
 
2.1.Material 
 
2.1.1. Cell lines  
      CGR8 ES cells were obtained from the European collection of cell culture 
(ECACC), ECACC No: 95011018. 
HEK293T cells, L929 cells NCTC clone L13, C57SV and BALB/cSV fetal fibroblasts, 
SV40-transformed mKSA tumor cells and methylcholanthrene-induced MethA tumor 
cells are from the Institute for Medical Microbiology, Immunology and Hygiene, 
Medical Centre, University of Cologne.  
 
2.1.2. Mice 
     Six to eight weeks old C57BL/6 and BALB/c mice were obtained form Charles 
River (Sulzfeld, Germany). 129P2/OlaHsd and Beige Mice were obtained form Harlan 
Laboratories (the Netherlands). Breeding pairs of IL-10 deficient (IL-10-/-) mice of the 
BALB/c strain were kindly provided by Werner Müller, Institute for Genetics, Cologne, 
Germany, and Donna Rennick, DNAX, Palo Alto, California (Kuhn et al., 1993). The 
mice were heterozygously mated so that wt littermates were used as controls. 
Breeding pairs of perforin-deficient mice on the C57BL/6 background were a kind gift 
of Hans Hengartner, Institute of Experimental Immunology, University Hospital 
Zürich, Switzerland (Kagi et al., 1994). Mice with a T cell-specific inactivation of the 
IL-10 gene (IL-10FL/FLCD4-Cre+) were described previously (Roers et al., 2004). 
Perforin-deficient and IL-10FL/FLCD4-Cre+ mice were backcrossed ten times to the 
BALB/c background in the animal facilities of the Center for Molecular Medicine 
Cologne. All mice were bred and kept strictly under barrier conditions and were used 
when 8 to 12 weeks old. Mice were housed under specific pathogens free conditions 
at the animal facility of IMMIH and fed with standard pellet food. Animal experiments 
were approved by the ethics committee of the Bezirksregierung Köln and were 
performed in accordance with the German animal protection law.  
 
2.1.3. Plastic ware 
Cell culture dishes    Nunc 
Pipettes     CELLSTAR 
Pipette tips     CELLSTAR 
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Centrifugation tubes   Falcon and Eppendorf 
Glass materials    Schott 
 
2.1.4. Technical equipment 
 
Appliance     Name     Supplier 
Centrifuge     5417 R     Eppendorf  
Centrifuge    Megafuge 1.oR     Heraeus  
ELISA reader   MRX TC    Dynex  
Fluorescence microplate reader  victor 1420    Wallc 
Flowcytometer   FACSCalibur   BD 
Gama counter   COBRA II    Canberra-P 
Gel chamber    Agagel Midi     Biometra  
Gel documentation apparatus Chemidoc     BioRad  
Incubator    Heracell     Heraeus  
Microscopes     TC SL     Leica 
Photometer     Smart      BioRad  
Power supply    EPS-3501 XL    Pharmacia 
Shaker     Bühler Schüttler    Johanna Otto  
Sterile hood     Herasafe (vertical)    Heraeus   
Thermocycler   T3-Thermocycler   Biometra 
Ultracentrifuge   Discovery 90SE   Sorvall 
 
2.1.5. Chemicals and reagents 
   All chemicals were off research grade. All Buffers and solutions were prepared by 
using deionised or bidistilled  water from an EASYpure UV/UV water purification unit 
(Werner Reinstwassersysteme. Leverkusen), sterilized by autoclaving or sterile 
filtered with a 0,2 μm filter if necessary and stored at room temperature. 
 
Acetic acid      Sigma 
Agar       Neuform 
Agarose       BMA  
CA-074      Bachem 
CA-074Me      Bachem 
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Crystal violet      Merck 
CTL       BioRad 
Dithiothreitol (DTT)     Sigma 
DMEM (Dulbecco MEM)    Invitrogen  
DMSO (dimethylsulfoxide)    Sigma 
DNA ladder 1kb plus     Fermentas  
DNA loading buffer (6x)     Fermentas  
dNTPs       Peqlab  
EDTA       Sigma  
EGTA       Merck 
Ethanol       Merck  
Ethidiumbromide      Sigma  
Fetal calf serum (FCS)    Invitrogen  
G418       PAA Lab  
Gelatine type A      Sigma 
Glycerin      Merck 
Glycerol       Sigma  
Hanks’ Balanced Salt Solution    Sigma  
HEPES      Serva 
Hoechst 33258     Sigma 
Isopropanol       Sigma  
KCl       Sigma 
L-glutamine       Invitrogen  
LIF       ESGRO; Chemicon  
Methyl cellulose     Merck 
MgCl2       Invitrogen  
Moninsin      Sigma 
mrIFN-γ      R&D 
Na2HCO3       Sigma  
NaCl       Merck 
NaHCO3       Sigma  
Non-essential amino acids    Invitrogen  
Paraformaldehyde      Sigma  
PBS (for cell culture)     Invitrogen  
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Penicillin/Streptomycin    Invitrogen  
Polybren      Sigma 
Reverse Transcriptase     Roche  
RNAse inhibitor      Roche  
RT-buffer       Roche  
SDS       Sigma 
Sodium pyruvate      Invitrogen  
Taq DNA polymerase     Invitrogen  
TEMED      Merck 
Triton-X-100      Sigma  
Trypsin-EDTA (10x)     Invitrogen  
Trypton      Neuform  
Tween      Merck 
Yeast extract     Neuform 
β-Mercaptoethanol      Invitrogen, 0,02 in water, stored at 4°C 
 
2.1.6. Cell culture medium, reagents and buffers 
All buffers and reagents were made using deionised double distilled water from the 
EASY-pure UV/UF water purification unit.  
 
2.1.6.1. Cell culture media 
Cultivation medium for ES cells Glasgow                         MEM 90% (v/v) 
       FCS 10% (v/v) 
                    L-glutamine 2 mM 
                    ß-mercaptoethanol 50µM 
                    LIF 100U/ml 
 
Cultivation medium for EB (EB medium)                          Iscove’s MEM+GlutaMAX                
                                                                                          80% (v/v) 
                    FCS 20% (v/v) 
                    β-mercaptoethanol 100 µM 
                    non-essential amino acids  
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Cultivation medium for C57SV,                                        DMEM 95% (v/v) 
BALB/cSV fibroblasts,  MethA tumor cells                       FCS 5% (v/v) 
mKSA tumor cells                                                            Penicillin 50mg/ml 
                                                                   Streptomycin 50mg/ml 
 
Freezing medium for cells                                                Glasgow MEM 70% (v/v) 
                                                                    DMSO 10% (v/v) 
                                                                    FCS 20% (v/v) 
 
 
 
 
 
2.1.6.2. Cell culture reagents 
Gelatine type A for coating cell culture plastics          Gelatine type A 0.1% in ddH2O 
                                                              Incubation: 30 min, 37°C 
                                                                          
Trypsin 1x                                                                   10ml of Trypsin 10x made up to      
                                                                                    100ml using ddH2O 
 
2.1.6.3. Bacteria culture media and reagents 
LB (Luria-Bertani) medium  10g/l trypton, 5g/l yeast extract and 5g/l             
                                                                  NaCl 
LB agar:   10g/l aga, 10g/l trypton, 5g/l yeast extract    
                                                                  and 5g/l NaCl 
S.O.C medium                                           (Invitrogen) 
 
 
2.1.7. Reagents for molecular biology 
Tris-EDTA (pH 8.0)  Tris 10 mM, EDTA 1 mM in ddH2O 
TAE (pH 7.8)             Tris-HCl 40 mM, Acetic acid 5 mM, EDTA 1 mM,    
                                           in ddH20 
 
 12
                                                                                                    Material and Methods  
2.1.8. Antibodies  
Antibody                                           Application                           Provider 
Ms. Anti SSEA-1 (clone MC-480)       FACS 1:1000                        R&D  
PE-anti-H-2Kb clone AF6-88.5           FACS                                    BD 
mAb GB12 against human                                                                  
granzyme B                                        FACS                                    Caltag   
CD3, CD8a, CD8b, TCRα/β,              FACS                                    BD 
TCRγ/δ, CD44, CD62L, CD69,  
CD103 
 
2.1.9. Primers for real time PCR 
GranzymeM 
Grz.M Fr.         5’ TTG AGA CCC AGA TCA TTG 3’ 
Grz.M Rev.      5’ ATA CCC ACT TCC GAT GCA CA 3’ 
Grz.M P           (6-FAM)CAC TCC CGC CCA TAC AT(TAMRA-6-FAM)    (Operon) 
 
Serpin 6        gene expression assay (Appliedbiosystems)     
Serpin9b       gene expression assay (Appliedbiosystems) 
18s rRNA gene expression assay (Appliedbiosystems) 
β-actin           gene expression assay (Appliedbiosystems) 
GAPDH         gene expression assay (Appliedbiosystems)                 
 
2.1.10. Plasmids 
Entry vector pENTER/siH1  
Size: 4636 bp 
Resistance gene: Kanamycin. 
 
Destination vector pLPac/EGFP 
Size: 9564bp 
Resistance gene: Blasticidin 
(all plasmids were kindly provided by B. Yazdanpanah from IMMIH) 
pLPac/EGFP/sh-SPI-6             (kindly provided by Zeinab Abdullah) 
Packaging vectors  
pLP1, pLP2 and the envelope plasmid pLP/VSVG (Invitrogen) 
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2.1.11. Kits 
NK1.1. cell Isolation kit                                                            Miltany Biotec      
ELISA mouse IFNγ OptEIA kit                                                 Becton Dickinson                                
RNeasy Mini kit                                                                       Qiagen                  
Quantitect reverse transkription kit                                         Qiagen                 
RiboGreen RNA quantification kit                                           Molecular Probes 
QIAprep spin Minipräp kit                                                        Qiagen    
Plasmid Maxi präp kit                                                              Qiagen 
PKH67 green Fluorecent Cell Linker kit                                  Sigma 
for general cell membrane labeling 
 
 
2.2. Methods 
2.2.1. Cell Culture 
     Cell culture was performed under sterile conditions in a sterile hood with sterile 
media and plastics. Cells were cultivated in an incubator at 37°C, 5% CO2 and 
humidified air. 
CGR8 cells were maintained in tissue culture flasks coated with 0,1% gelantine in ES 
cell medium. Medium was changed daily and ES cells were passaged every 3-4 
days. 
Balb/cSV fibroblasts, C57BL/6 fibroblast , YAC cells,  mKSA tumor cells and MethA 
tumor cells were maintained in tissue culture flasks in 5% DMEM. 
 
2.2.2. In vitro differentiation of ES cells into embryoid bodies 
     For the in vitro differentiation of CGR8 ES cells into embryoid bodies, a single cell 
suspension of ES cells was adjusted to a final concentration of 2,5x104 cells/ml in EB 
medium. 
20μl drops containing 500 cells were placed on the cover of petri dishes. After two 
days the ES cells had formed cell aggregates that were transferred into bacterial petri 
dishes to avoid adherence. 
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2.2.3. Cloning efficiency assay 
      The elimination of mKSA tumor cells from the peritoneal cavity was assessed by 
a cloning efficiency assay. Briefly, peritoneal exudate cells were collected at the 
indicated days after challenge, adjusted to 106 Trypan blue excluding cells per ml and 
serially ten-fold diluted. Aliquots of each dilution were plated in 6-well plates and 
cultivated in complete medium for 8 days. Afterwards, the cells were fixed and 
stained with Crystal violett. Clonally expanded mKSA colonies were counted to 
calculate the number of proliferating mKSA cells that were contained within 106 
peritoneal exudate cells at the day of the peritoneal lavage.  
 
2.2.4. Production and purification of recombinant T-Ag 
       T-Ag was produced by infecting Sf 158 cells with recombinant baculovirus coding 
for full length SV40-T-Ag (Lanford et al., 1988), kindly provided by Dr. Ellen Fanning. 
T-Ag was purified from cell lysates by immunoaffinity chromatography using PAb 108 
coupled to CNBr-Sepharose. The purified protein was dialyzed against PBS/40% 
glycerine and stored at -70oC.  
 
2.2.5.Treatment of ES cells 
2.2.5.1. Induction of MHC class I molecules on the surface of cells 
    To induce expression of MHC class I on the cell surface, cells were incubated with 
20ng/ml IFNγ for 48 hours before the experiment. The expression of MHC class I 
molecules on the cell surface was measured by flow cytometry. 
 
2.2.5.2. Blocking of Cathepsin B 
ES cells were pre-treated with 10μM CA074 16 h prior to experiment. 
 
2.2.6. PCR 
2.2.6.1. RNA isolation 
     Total RNA was extracted from approximately 2x106 ES cells, day 5 EB cells, 
Balb/cSV fibroblasts, resting NK and activated NK cells using the RNeasy mini elute 
kit (Qiagen) according to manufacturers instructions (spinning protocol). 
For the isolation of RNA from Placenta the RNeasy midi kit was used (Qiagen). 
 15
                                                                                                    Material and Methods  
2.2.6.2. RNA quantification 
     Isolated RNA was quantified using the RiboGreen RNA quantification kit 
(Molecular Probes) in a 96-well microplate. 5μl RNA and 95μl TE buffer were 
distributed per well. RiboGreen reagent was diluted 1:200 and 100μl was added per 
well. Plates were incubated 2 min at room temperature and then excited at 458 nm. 
The fluorescence emission intensity was measured at 525 nm using the fluorescence 
microplate reader (Wallac victor multilabel counter 1420). RNA  concentrations were 
measured by comparing with a standard curve. 
 
2.2.6.3. cDNA synthesis 
     To circumscribe RNA into cDNA the reverse ranscription kit Quantitect (Qiagen) 
was used according to the manufactures instructions. 
 
2.2.6.4. Real time PCR (TaqMan) 
     Quantitative real-time PCR was performed with the TaqMan ABI-Prism 5700 
Sequence Detection System (Applied Biosystems). Following the instructions of 
Applied Biosystems the optimal concentration for each primer pair and probe were 
determined. In each PCR-reaction negative and positive control templates were 
included. Reactions were carried out in 25μl mixture  using the TaqMan Universal 
Master Mix (Applied Biosystems) according to the manufacturers instructions. 
 
Components of the real time PCR reaction mixture were as follows: 
 
2,5μl cDNA (final concentration: 5 ng/ml) 
12,5μl PCR Master Mix 
250μM Forward Primer 
250μM ReversePrimer 
300μM Fluorogenic Probe 
8,5μl water 
     Total volume: 25μl 
 
Individual steps: 
 
50°C       120sec      UDG PCR decontamination 
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95°C       120sec      Taq start activation 
 
40 Cycles : 
 
95°C       15sec        Denaturation 
60°C        60sec       Annealing and Extension 
 
     mRNA was calculated for each gene by using a standart curve. The value 
obtained for each gene was normalized to that of the housekeeping gene encoding 
GapDH and β-actin. Then the fold change was calculated using crossing threshold 
(Ct) values.  
 
2.2.7.Treatment of mice 
2.2.7.1. Immunization of mice with recombinant T-Ag and challenge with mKSA     
            cells 
        Ten μg of purified T-Ag in PBS were injected twice i.p. in a one-week interval 
(days -14 and -7). Seven days after the second immunization (day 0), the animals 
were challenged by i.p. injection of 106 viable mKSA cells, which equals the 10,000-
fold LD50 of these tumor cells (Baschuk et al., 2007).  
 
2.2.7.2. Depleting mice of CD4+ or CD8+ T lymphocytes 
         Groups of mice were i.v. treated with either a mixture of each 250µg rat mAb 
YTS191.1 and YTA3.1(Qin et al., 1987), or 500 µg rat mAb YTS169.4 (Cobbold et 
al., 1984) to deplete CD4+ or CD8+ T lymphocytes, respectively. As a control purified 
rat IgG (Sigma, Deisenhofen, Germany) was administered in some experiments. The 
time of the Ab injection relative to tumor challenge is given in the results section. mAb 
were produced, purified, used, and efficacy-controlled as described (Gegin et al., 
1992). 
 
2.2.7.3. Activation of NK-cells 
       To otain activated NK cells adult mice (6-8 weeks of age) were infected with the 
LCMV, strain WE. Plaque forming units (PFU) were converted into infectious units 
(IU) by multiplying PFU with a factor of 10. Mice were infected by intravenous (i.v. ) 
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inoculation of 1x105 IU of the LCMV in 0,3 ml PBS with 5% penicillin/streptomycin 
(PS) and 1% fetal calf serum (FCS) into the tail vain. 
Or Mice were intraperitonelly (I.p.) injected with 250 μg polyI:C in 500μl PBS. 48 
hours later mice were sacrificed and activated NK cells were isolated. 
 
2.2.8. Isolation of effector cells 
2.2.8.1. Preparation of resting and activated NK cells from spleens  
       Mice were sacrificed and their spleens were removed. Single cell suspension 
was optained by passing spleens through a 70μm pore size cell mesh in cold RPMI. 
Cell suspensions were centrifuged at 1000 rpm for 5 min at 4°C. Cell pellet  was 
resuspended in 10 ml cold 0,2% NaCl to lyse erythocytes and after 20 seconds the 
lysis was stopped with 1,6% NaCl. Cells were pelleted again by centrifugation and 
resuspended in RPMI. Cell number was determined using trypan blue exclusion 
method in a Neubauer chamber. NK cells were enriched from the splenic cell 
suspension using anti NK monoclonal antibodies conjugated to magnetic beats 
(Miltany Biotec) following manufactures instructions. Following the incubation time 
cells were washed 3 times and loaded on large MACS columns under a magnetic 
field. The columns were rinsed several times, removed from the magnetic field and 
NK cells were eluated in sorting buffer. Cells were pelleted in RPMI and cell number 
was determined using trypan blue exclusion method in a Neubauer chamber. 
 
2.2.8.2. Isolation of Tumor Associated Lymphocytes ( TAL) 
      T-Ag-immunized or naive mice were inoculated i.p. with 106 mKSA tumor cells. 
Peritoneal exudate cells (PEC) were recovered by rinsing the peritoneal cavities with 
cold PBS. 
 
2.2.8.3. Isolation of mouse small intestinal intraepithelial lymphocytes (IEL) 
     IEL were prepared according to Montufar-Solis et al. with minor modifications. In 
brief, after removal of small intestines, Peyers patches were dissected. Fecal material 
was flushed off with RPMI 1640 supplemented with FCS (10% v/v), 100 U/ml 
penicillin-streptomycin and 5x10-5 M 2-ME. Subsequently, intestines were opened 
longitudinally and cut into pieces of 0.5cm length. The tissue fragments were rinsed 
several times in Ca2+/Mg2+-free PBS and stirred at 37°C for 20 min in Ca2+/Mg2+-free 
PBS containing 5mM EDTA and 2mM DTT. The resulting cell-suspensions were 
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vortexed for 15 seconds, and supernatant was collected. The last step was repeated 
and supernatants were combined before centrifugation at 1000 rpm, 4°C for 5min. 
Cells were filtered through a 10 ml syringe barrel containing wetted nylon wool and 
centrifuged again. The cell pellet was suspended in 40% isotonic Percoll, layered on 
top of a 70% Percoll cushion, and centrifuged for 20 min at 600xg. IELs were 
harvested from the Percoll interface and suspended in complete RPMI. 
 
2.2.9. Magnetic cell sorting  
    NK cells, TAL or IELs  were enriched from the splenic cell suspension, peritoneal 
exudates cells or intestinal single cell suspension using anti NK monoclonal 
antibodies, CD4 or CD8 mAb conjugated to magnetic beats (Miltany Biotec) following 
manufactures instructions. Following the incubation time cells were washed 3 times 
and loaded on large MACS columns under a magnetic field. The columns were 
rinsed several times, removed from the magnetic field and NK cells were eluated in 
sorting buffer. Cells were pelleted in RPMI and cell number was determined using 
trypan blue exclusion method in a Neubauer chamber. 
 
2.2.10. Chromium release cytotoxic assay  
2.2.10.1.Effector cells 
     Effector cells were magnetically enriched as described in 2.2.9. Effector cell 
number was adjusted to 3x106 cells/ml in RPMI, 200μl  were dispensed in U-bottom 
96 well plates in four replicants and serial dilutions of 1:2 in RPMI were made three 
times. 
 
2.2.10.2. Target cells 
        To obtain the specific cytotoxic activity of effector cells, target cells were 
adjusted to 106/ml and then incubated with 50μCi 51CR for 60minutes at 37°C. Cells 
were washed three times to remove the extra cellular 51Cr. Cell numbers were 
adjusted to 3x104/ml and 100μl of the target cell suspensions were dispensed to the 
previously distributed efector cells in the 96-well plate to obtain Effector : Target cell 
ratios of 100:1, 50:1, 25:1and 12,5:1. The spontaneous release of  each 51Cr-labeled 
target cell was determined in 8 wells without effector cells.  In these samples the 
spontaneous release was less than 9% of the maximum release. The maximal  
release  was determined by the total target cell lysis in 1,6% Triton-X-100 in water. 
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After 4 h incubation at 37°C, cells were spun down and 100μl of the cell-free 
supernatants were harvestet. A probe from each well were measured in a gamma-
counter to detect the amount of 51Cr as counts per minute (cpm).  Mean of the four 
replicates were calculated with correction for background lysis, as followes for esch 
effector to target cell ratio: 
 
           % specific lysis = (cpm sample-cpm spontan)  / (cpm maximal-cpm spontan) x 100 
 
2.2.11. Flow cytometry 
2.2.11.1. Surface staining   
      CD8+ IEL, were phenotypically characterized by surface staining with mAb 
specific for CD3, CD8a, CD8b, TCRα/β, TCRγ/δ, CD44, CD62L, CD69 or CD103. A 
total of 1x106 cells was washed with PBS, 0,5% BSA and stained for 15 min with 1μg 
of fluorochrom-labeled monoclonal antibody. 
 
2.2.11.2 Flow cytometry analysis of MHC class I expression  
    Flow cytometry analysis of MHC class I expression on the surface of cells. Single 
cell suspensions of ES or EB cells were stained with monoclonal antibody specific for 
H-2Kb  or isotype control antibodies and were analyzed by FACScan and CellQuest 
software.  
 
2.2.11.3. Flow cytometric analyses, quantification of cytokines and of cytokine-    
               secreting T cells, and histopathology 
     For detection of intracellular IFN-γ , granzyme B and A CD8+ T-cells were 
immunomagnetically enriched from PEC and were incubated on a confluent 
monolayer of mKSA cells in six-well plates (Nunc, Roskilde, Denmark) for 1 h. 
Thereafter Golgi-Stop reagent was added, and the cultures were incubated for further 
5h (only for IFN-γ). The T cells were harvested by gently rinsing the plates with 
medium, stained with anti-CD8 mAb, fixed, permeabilized and stained for intracellular 
IFN-γ,  granzyme B or granzyme A. The frequency of CD8+ IFN-γ+ or CD8+ granzyme 
B+ or A+  T-cells was determined with a FACSCalibur (BD Biosciences, Heidelberg, 
Germany) flow cytometer. TAg-expressing mKSA tumor cells were visualized in 
specimens of intraabdominal tissues and organs by immunostaining with polyclonal 
rabbit antiserum R15 against Tag or CD8-specific mAb. 
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2.2.12. Quantification of cytokines and cells secreting cytokines 
      For the quantification of IFN-γ, IL-4 or IL-10 secreted by resting or activated NK 
cells or TAL, IFN-γ, IL-4 or IL-10 specific ELISA kits (R&D) were used following the 
manufacturer's instructions. Cocultures were centrifuged for 3 min at 310 g at 4°C 
and cell-free supernatants were collected and stored at -80°C if test was not 
performed immediately. 
The fraction of CD8+ TAL or IEL secreting IFN-γ in response to mKSA tumor cells 
was determined by an IFN-γ-specific Elispot assay (R&D systems) on day 8 or 2 after 
challenge of TAg-immune mice with 106 mKSA cells. The immunomagnetically 
enriched CD8+ TAL or IEL were incubated at graded densities with 105 mKSA cells 
and the assays were developed according to the instructions of the manufacturer.  
 
2.2.13. Quantifying enzymatic activity 
2.2.13.1. GzmM specific activity 
       Enzymatic activity of granzyme M in the lysates  of 5x105 resting NK cells, poly 
I:C activated NK cells and of CD8+ CTL on day eight after LCMV infection was 
analysed by cleavage of the chromogenic substrate Boc-Ala-Ala-Met-SBzl. Substrate 
cleavage was followed by using absorption 405nm. 
 
2.2.13.2. GzmA- and -B-specific enzymatic activity 
     In lysates of CD8+ TAL the gzmA- or -B-specific activity was determined by using 
substrate H-D-Pro-Phe-Arg-p-nitroanilide (S2302; manufactured by Chromogenix, 
Lexington, MA, USA) or N-acetyl-Ile-Glu-Pro-Asp-p-nitroanilide (Biomol, Exeter, UK), 
respectively, according to instructions of the manufacturers. 
 
2.2.14. Transient down regulation of Serpin-CI in ES cells by RNAi 
2.2.14.1. Preparation of siRNAs 
       Two different siRNAs coding for SPI-CI and negative controls, including Alexa 
Fluor 488 at the 3’ prime end of the sense stand (Qiagen) with the following Target 
sequences were used: 
 
        1.)  TAA ATT TAA ATT TAC AAA CAA 
               Sense :         r(AAU UUA AAU UUA CAA ACA A)dTdT 
               Antisense :   r(UUG UUU GUA AAU UUA AAU U)dTdT 
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           2.)  TGC AAC TTA TCT TGT AAC AAA 
                Sense:         r(CAA CUU AUC UUG UAA CAA A)dTdT 
                Antisense:   r((UUU GUU ACA AGA UAA GUU G) dTdT 
 
Both siRNAs were diluted in siRNA suspension Buffer to a final concentration of 
20μM and stored at -20°C according to the manufacturers instructions. 
 
2.2.14.2. Transfection of ES cells with siRNAs 
     On the day of transfection 5x105 CGR8 cells were plated on a 6cm gelantine 
coated plate. Immediately 0,5μg siRNA was diluted in ES cell medium, mixed with 
Hyperfect (Qiagen) as a transfection reagent and incubated 10 min at room 
temperature. After the incubation time the transfection mix was distributed drop wise 
on the cell suspension. 
After a 24 h incubation time the medium was changed, and 48 h later ES cells were 
trypsinized and analysed for the down regulation of SPI-CI  by TaqMan-PCR or used 
as target cells in the chromium release assay. 
 
2.2.15. Stable down regulation of  Serpin-CI in CGR8 cells 
     For stable expression of siRNA in ES cells a Lentiviral vector was constructed. 
 
2.2.15.1. Design of shRNA constructs 
     The murine SPI-CI specific and the murine specific small hairpin RNA were 
designed following the pSUPER RNAi system of OligoEngine. Targeted sequences 
are specific for murine SPI-CI and SPI-6/SPI-CI as no other matche was found using 
the BLAST database of the national Center for Biotechnology Information 
(htt://www.ncbi.nlm.nih.gov).As a negative control non specific shRNA (scrSPI-CI) 
was designed. The oligonucleotides were as follows: 
for SPI-CI 
M_Serbin9b_si-SP:   5’-GAT CCC CCA ACT TAT CTT GTA ACA AAT TCA AGA 
GAT TTG TTA CAA GAT AAG TTG TTT TTA-3’  
M_Serbin9b_si-ASP:   5’-AGC TTA AAA ACA ACT TAT CTT GTA ACA AAT CTC 
TTG AAT TTG TTA CAA GAT AAG TTG GGG-3’ 
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Serpin_scr_SP:         5’-GAT CCC CAT ACT AGA ATT CAT CAA CTT TCA AGA 
GAA GTT GAT GAA TTC TAG TAT TTT TTA-3’ 
Serpin_scr_ASP:        5’-AGC TTA AAA AAT ACT AGA ATT CAT CAA CTT CTC 
TTG  AAA GTT GAT GAA TTC TAG TAT GGG-3’ 
 
For SPI-6/CI 
M_Serbin6/9b_si-SP:     5’-GAT CCC CCT TGT GAA GTC CTC CAA ACT TCA AGA 
GAG TTT GGA GGA CTT CAC AAG TTT TTA-3’ 
M_Serbin6/9b_si-ASP:   5’-AGC TTA AAA AGA ACA CTT CAG GAG GTT TGT CTC 
TTG AAC AAA CCT CCT GAA TGT TTC GGG-3’   
 
Each sense an anti-sense primer pair was annealed to generate a double-stranded 
oligonucleotide by mixing 3 μg of each oligo with 5μl of 10x annealing buffer and 
PCR water to a final volume of 50μl. The mixture was incubated 4min at 95°C, 10min 
at 70°C, slowly cooled down to room temperature and then stored at-20°C. 
 
2.2.15.2. Ligation of the complementary DNA into the pENTR/siH1 plasmid 
        Following linearization of the pENTR/siH1 plasmid by BglII and HindIII restriction 
enzymes, the linearized plasmid was purified on 1% agarose gel (fragment size 
4,400 bp) using gel extraction kit (Qiagen) and concentration was adjusted to 500 
ng/µl. For the ligation of the annealed oligos into the linearized plasmid 2 µl of the 
annealed oligos were mixed with 1 µl T4 DNA ligase (Invitrogen), 1 µl of the ligase 
buffer (Invitrogen), 1 µl of the linearized plasmid and 5 µl water. Mixture was then 
incubated overnight at room temperature. 
Recombinated vectors were then transformed into chemically competent DH5α by 
adding 5 µl of the ligation reaction to one aliquot (100 µl) of cells and incubated for 30 
min on ice, 95 sec at 42°C and finally for 3 min on ice. Cells were centrifuged for 2 
min at 1000 g and 500 µl of the supernatant was discarded. The pellet was 
resuspended in the rest of the supernatant and plated on LB agar containing 50 
mg/ml kanamycin and incubated for 24 h at 37°C. 
On the next day several colonies were picked and 3ml of LB broth containing 
50 mg/ml kanamycin were inoculated for each colony and grown overnight at 37°C 
with shaking. Plasmids were purified using the mini prep kit (Qiagen), eluted in water 
and stored at -20°C. Positive clones were checked for the presence of the insert by 
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restriction digestion with the BglII and HindIII enzymes. Positive clone gives rise to 
two fragments 227 bp and 4 kb. 
 
Fig.1. pENTR/siH1 vector 
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2.2.15.3. Construction of the destination vector 
    For the construction of the destination vector the Lentiviral vector pLenti6/EGFP 
was chosen. EGFP was cut out and firefly luciferase was cloned in. The 
oligonucleotides for firefly luciferase were as follows:  
fw primer ffluc:   5  -GAT CGC  TAG CGA GAA CGG TAC CAT GGA AGA - 3 
rev primer ffluc:  5  -GAT CCC GCG GTA CAA TTT GGA CTT TCC GCC  - 3 
 
2.2.15.4. Recombination of the entry vector into the destination vector using         
              the Gateway system 
      For a stable transcription of the SPI-CI-specific shRNA, the entry plasmids were 
cloned into the Lentiviral vector pLenti6 /ffluc using the Gateway system (Invitrogen).  
In 200 µl PCR microtubes, 1.5 µg of entry plasmid, 1.5 µg of destination vector, 1 µl 
of 5x LR Clonase II enzyme (Invitrogen) and 1 µl TE-buffer pH 8 were incubated 
overnight at room temperature. On the next day 1 µl of proteinase K was added and 
tubes were incubated at 37°C for 15 min.  
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essing Lentiviral vector pLPac/ffluc/sh-SPI-CI 
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   [modified by B. Yazdanpanah from the pLenti/delta UBC/V5-DEST vector from Invitrogen] 
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 25
                                                                                                    Material and Methods  
    For the production of Lentivirus particles the ViraPowerTM Lentiviral expression 
system (Invitrogen) was used. HEK293T cells were detached and single cell 
suspension was adjusted to approximately 6x105 cell/ml in DMEM (without G418). In 
a 10 cm petri dish, 10 ml of the cell suspension was applied and directly co 
transfected with 3 µg pLPac/ffluc/sh-SPI-CI  or pLPac/ffluc/scr-shSPI-CI, 1 µg of each 
of the packaging plasmids pLP1, pLP2 and the envelope plasmid pLP/VSVG 
(Invitrogen).  
Supernatants containing the virus were collected after 48 h and 72 h, pooled, 
centrifuged for 15 min at 600 g at 4°C and filtered using 0.45 µm filters to remove any 
cells or cell debris. To enrich for virus, supernatants were centrifuged for 2 h at 60000 
g at 4°C in an ultracentrifuge (Beckman). Supernatants were discarded and pellets 
were resuspended in 1 ml PBS for each 20 ml start volume. Aliquots of 100 µl were 
then stored at -80°C. 
 
2.2.15.5. Transduction of CGR8 ES cells 
The day prior to transduction, 5 × 105 CGR8 ES cells were plated in 10 cm petri 
dishes coated with gelatine. The next day, Lentivirus stocks were thawed on ice and 
virus titers were adjusted to 1x105 TU/ml in ES cell medium. 5 ml of the virus solution 
were added to each plate together with 10 µg/ml of polybren (Sigma). Cells were 
plated and incubated at 37°C for 48 h, later cells were detached and a single cell 
suspension of 2.5 x103 cell/ml was made in ES cell medium containing 4,5 µg/ml 
blasticidin. In 96-well plates coated with gelatine 100 µl of the selection medium was 
dispensed per well. 100 µl of the neat cell suspension was dispensed in the first well 
1:2 serial dilutions were made by dispensing 100 µl in each step. Single-cell colonies 
were isolated and plated in 6 cm plates and selected further for blasticidin resistance. 
After 14 days, SPI-CI expression was assessed in different clones using real time 
PCR.  
 
2.2.16. In vivo bioluminescence imaging 
   mKSA cells stably expressing luciferase were generated by transduction with a 
recombinant lentivirus coding for luciferase of Renilla renifares. This virus was 
constructed from a PCR derived fragment encoding the luciferase (Promega GmbH, 
Mannheim, Germany) cloned into an entry vector (Invitrogen) and recombined with 
the gateway destination vector p-lenti Dest6/V5 (Invitrogen) according to the 
manufacturer’s instructions. This construct and packaging plasmids were used to co-
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transfect the HEK 293 FT producer cell-line. Supernatant containing lentiviral 
particles was harvested and used to tranduce mKSA tumor cells from which positive 
clones were selected with 10μg/ml Blasticidin (Invitrogen). 
Dissemination of Renilla luciferase-expressing mKSA cells within the peritoneal 
cavity was monitored non-invasively by bioluminescence imaging with the in vivo 
imaging system IVIS (Xenogen). Mice were i.v injected with coelenterazine 
(Promega) at a dosage of 1,5 μg/g bodyweight, anesthetized with isoflurane and 
imaged for bioluminiscence for 1min exposure time. Optical images were analyzed by 
IVIS living image software package. 
 
2.2.17. Cytotoxic in vivo assay 
     Wild type ES cells, shSPI-6 ES cells, shSPI-CI ES cells, shSPI-6/SPI-CI cells, 
scrambled control ES or YAC cells were labelled with PKH67, according to the 
manufacturers instruction, and adjusted to 2x107cells per ml. Activated or resting 
C57BL/6 mice or perforin-/- or beige mice were injected with 1x107 cells, of one cell 
type in 0,5 ml per mouse, by intravenous inoculation. 30 minutes and 4 hours after 
inoculation, mice were killed and the total number of living fluorescent cells per 
spleen was ascertained by FACS-Analysis.  
 
2.2.18. statistical Analysis 
   For statistical Analysis, the data were subjected to two-tailed Student’s t-test. The 
survival data were analysed according to Kaplan-Meier and statistical significance 
was determined by log-rank tests. 
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3. RESULTS I 
 
3.1. CD4+ TAL from TAg immune BALB/c mice secrete IL-4 during antigen-    
       specific rejection of mKSA tumor cells 
 
   Primary CD4+ T cells, harvested by peritoneal lavage from the tumor site between 
days 4 to 14 after i.p. challenge of TAg-immune BALB/c mice with 106 viable mKSA 
tumor cells, secrete large amounts of IL-4 (Fig. 1). IL-4 secretion correlates with the 
immune response mounted against mKSA cells, as CD4+ T cells harvested before 
challenge with mKSA tumor cells (Fig. 1, day 0 of tumor rejection) secrete only 
minute amounts of IL-4. Interestingly, CD8+ T cells did neither spontaneously nor in 
response to stimulation with mKSA cells or with PMA/ionomycin secrete IL-4 as 
determined by ELISA (data not shown). 
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FIG. 1. Primary CD4+ TAL from TAg-immunized BALB/c mice secrete IL-4 after challenge with     
            mKSA.  
BALB/c mice were immunized on days -14 and -7 by i.p. injection of 10μg TAg and challenged i.p. on 
day 0 with 10
6
 mKSA cells. CD4+ T cells were immunomagnetically enriched from peritoneal exudate cells 
collected prior to challenge (day 0; cells pooled from 15 mice) or  on days 4, 6, 8, or 14 after challenge 
(pooled from 5 mice per day). The CD4+ 6 TAL were kept at a densitiy of 1 x10  cells/ml in complete RPMI 
medium without any further stimuli for 24h. The contents of IL-4 in the cell-free supernatants of these 
cultures were determined by ELISA. Shown are the means and standard error of the mean of  three 
independent experiments.  
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3.2. IL-4 is not required for the rejection of mKSA tumor cells by TAg-immune     
       BALB/c mice 
 
+   In order to investigate the biological relevance of IL-4 secreted by CD4  TAL during 
TAg-specific rejection of mKSA tumor cells in BALB/c mice, the survival of TAg-
immunized IL-4-/- and wild type (wt) BALB/c control mice was monitored. Both TAg-
immunized IL-4-/- 6and wt mice survived an i.p. challenge with 10  mKSA tumor cells 
without any clinical signs of tumor growth for more than 60 days after challenge (Fig. 
2A and B). Non-immune IL-4-/-, as well as wt mice died between days 16 to 20 after 
challenge. Similarly, the maximal intraperitoneal tumor burden on day 4 after 
challenge as well as the kinetics of tumor cell elimination were comparable for TAg-
immune IL-4-/- and wt mice (Fig. 2C). These data clearly indicate that IL-4 is not 
essential in TAg-immune BALB/c mice for rejection of a dose of mKSA tumor cells 
equalling the 10,000-fold LD50 (data not shown) of these cells in naïve mice, although 
this cytokine is secreted in large amounts by CD4+ TAL during this immune 
response.  
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FIG. 2. TAg-immune IL-4-/- BALB/c mice are fully protected against challenge with 106 viable mKSA      
            tumor cells.  (legend on next page) 
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FIG. 2. TAg-immune IL-4-/- BALB/c mice are fully protected against challenge with 106 viable mKSA      
            tumor cells.  
   Groups of IL-4-/- and  wt BALB/c mice  were immunized on days -14 and -7 by i.p. injection of 10μg TAg 
and  challenged i.p. with 10
6
 mKSA cells on day 0. Survival of (A) IL-4-/-  and (B) wt mice (immune n=5, 
non-immune n=3) was monitored daily up to 65 days after challenge. (C) On the indicated days after 
challenge, peritoneal exudate cells harvested by peritoneal lavage were plated in ten-fold serial dilutions 
on 6-well plates. After cultivation for 8 days the cells were fixed and stained with crystal violett and clonal 
colonies of mKSA cells were counted. Shown are cumulative data from three independent experiments 
with each symbol representing an individual mouse. 
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3.3. Enhanced resistance of naive IL-4-/- mice to challenge with low doses of  
       mKSA cells 
 
   To further investigate the biological relevance of IL-4 secreted during rejection of 
mKSA tumor cells in BALB/c mice, naive mice were challenged with low doses of 
mKSA cells. In preliminary experiments we established that i.p. inoculation of 100 
viable mKSA cells into naive BALB/c mice is lethal for about 50% of the mice 
between days 30 to 50 after challenge (data not shown). In naïve IL-4-/- mice 
challenged s.c. with 102 mKSA tumor cells a slightly retarded tumor growth as 
compared to wild-type mice was observed (Fig. 3A). Naive IL-4-/- and wild type mice 
then were challenged i.p. with 103 viable mKSA cells. As shown in Fig. 3B, IL-4-/- 
mice challenged with this tumor cell dose had a significant advantage in survival time 
over wild type mice. Furthermore, depleting naive IL-4-/- mice of CD8+ T cells by 
injecting a CD8-specific mAb one day prior to challenge with mKSA cells abolished 
this effect completely as compared to naive IL-4-/- mice treated with control IgG (Fig. 
3C). This finding clearly indicates that the prolonged survival of naive IL-4-/- mice is 
dependent on CD8+ T lymphocytes.  
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FIG. 3. Tumor growth following s.c. inoculation and survival of mice after i.p. injection of mKSA 
cells into naive IL-4-/- and wild-type mice.  (legend on next page) 
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FIG. 3. Tumor growth following s.c. inoculation and survival of mice after i.p. injection of mKSA 
cells into naive IL-4-/- and wild-type mice. 
   (A) Naïve IL-4-/- 2 (closed circles, n=11) or wild-type mice (open circles, n=12) were inoculated with 10  
viable mKSA cells s.c. in the back of the neck. At the indicated days after challenge the diameters of the 
tumors were determined in three dimensions with calipers and subsequently the tumor volume was 
calculated. (B) Groups of naive IL-4-/- (closed symbols, n=14) or wild-type mice (open symbols, n=11) were 
i.p. inoculated with 103 viable mKSA cells. The mice were monitored for the development of tumors and 
death daily. According to Kaplan-Meier analysis the mean survival time and the standard error were for the 
IL-4-/- group 40.14 +/- 4.38 days, and for the wild type 25.45 +/- 2.23 days with a statistical significance of 
p<0.01 in log-rank test. (C) Groups of  naive IL-4-/- (n=8) and wt (n=10) mice were i.v. treated with 500µg of 
either CD8-specific mAb or of control IgG one day prior to i.p. challenge with 103 mKSA cells. Treatment 
with the antibodies was repeated 8 days after challenge. The mice were monitored for the development of 
tumors and death daily. According to Kaplan-Meier analysis the mean survival time in days +/-  standard 
error and the statistical significance in the log-rank test were as follows: IL-4-/-: anti-CD8 treated 25.88 +/- 
0.79 versus control IgG 51.13 +/- 7.57, p<0.01; wt: anti-CD8 treated 25.80 +/- 1.29 versus control IgG 
36.90 +/- 6.08, p>0.05.01 in log-rank test. 
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3.4. IL-4-deprivation results in enhanced TAg-specific cytotoxic activity,    
       accompanied by an increase in the fraction of tumor associated CD8+ T    
       cells expressing granzymes A and B  
 
   In search for the mechanism by which endogenous IL-4 impairs resistance of 
BALB/c mice against mKSA tumor cells, we monitored the TAg-specific cytotoxic 
activity of CD8+ TAL in IL-4-/- and wild-type mice at days 5, 7, and 8 after challenge of 
TAg-immunized mice with mKSA cells (Fig. 4). On day 5 after challenge, CD8+ TAL 
did not exert any TAg-specific cytotoxicity regardless whether these TAL were 
prepared from IL-4-/- or wild-type mice (Fig. 4A).  However, starting from day 7 after 
challenge, CD8+ TAL from IL-4-/- mice exhibited a three- to five-fold enhanced TAg-
specific cytotoxic activity as compared to TAL from wt mice as judged by horizontal 
comparison of the effector: target cell ratio required to achieve a given percentage of 
specific target cell lysis (Fig. 4B-C). Additionally, treatment of immunized wt mice at 
the day of tumor challenge and three days thereafter with neutralizing IL-4-specific 
monoclonal antibody augmented the TAg-specific activity of CD8+ TAL to an extent 
comparable to that observed in IL-4-/- mice (Fig. 4C). Treatment of mice with control 
IgG did not enhance the TAg-specific cytotoxicity of CD8+ TAL (data not shown). The 
enhanced cytotoxic activity of CD8+ T cells from IL-4-/- mice was both TAg-specific 
and perforin-dependent as shown by use of TAg-negative, syngeneic MethA target 
cells and of the perforin-inhibitor concanamycin A, respectively (Fig. 4D). 
   Further characterization of the CD8+ T cell response revealed comparable total 
numbers of CD8+ TAL recovered from the peritoneal lavage of TAg-immune IL-4-/- or 
wt mice on day 8 after i.p. challenge with 106 mKSA tumor cells (Fig. 5A) and 
comparable expression levels of CD8 on the plasma membrane of these cells (Fig. 
5B). Flow cytometry confirmed that CD8+ + + T cells of both genotypes were CD3  CD8  
T cells that did not differ with regard to surface expression levels of the activation 
markers CD44 and CD62L (data not shown).      
   The fraction of TAg-specific CD8+ TAL from IL-4-/- and from wt mice was 
determined by flow cytometry of intracellular IFN-γ and by IFN-γ-specific ELIspot. The 
percentage of CD8+ TAL responding to co-incubation with TAg-expressing BALB/c-
SV40 fibroblasts in vitro by producing IFN-γ was comparable, regardless whether 
determined by flow cytometry or by an ELISpot assay (Fig. 5C and D).   We also 
attempted to quantify the number of TAg-specific CD8+ d TAL by the use of a H-2K -
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dpentamer with the only H-2 -restricted TAg-epitope identified so far, the subdominant 
epitope encompassing aa499-507 of TAg (TAg499-507) (Newmaster et al., 1998). 
However, as might have been expected from the report of Newmaster and 
colleagues  that TAg499-507-specific CTL can  only be detected after repeated in vitro 
restimulation of lymphocytes from BALB/c mice immunized with SV40 (Newmaster et 
al., 1998), TAg499-507-specific cells were not detectable in significant frequencies 
among the CD8+ TAL of TAg-immune IL-4-/- or wild-type mice challenged with mKSA 
cells (data not shown). 
+   Although the percentage of CD8  T cells expressing the cytotoxic effector molecule 
granzyme A, as determined by flow cytometry, was significantly enhanced for IL-4-/-  
CD8+ TAL as compared to wt cells on day 8 after challenge (Fig. 5E ),the gzmA-
specific enzymatic activity in lysates of these cells was not different between IL-4-/- 
and wt mice (data not shown). However, both the frequency of CD8+ T cells 
expressing gzmB as well as the gzmB-specific enzymatic activity were clearly 
enhanced for IL-4-/- CD8+ T cells (Fig. 5F). The data suggest that IL-4 deprivation 
increases the fraction of mature, i.e. lysis-competent CD8+ T cells expressing 
cytotoxic effector molecules in the CD8+ TAL population. 
   In search for the mechanism behind the enhanced tumor resistance of naïve IL-4-/- 
mice, CD8+ TAL from naïve mice challenged with 103 mKSA cells were analyzed on 
days 8, 14, and 21. The total number of CD8+ TAL was slightly increased in both wt 
and IL-4-/- mice on day 14 as compared to days 8 and 21 without showing significant 
differences between the genotypes (Fig. 6A). The low numbers of CD8+ TAL 
recovered on any of these days did not exert significant TAg-specific cytotoxic activity 
against mKSA cells as determined by chromium release assays (data not shown). 
However, in IL-4-/- mice the frequency of CD8+ TAL expressing gzmA significantly 
(p<0.01) increased between days 8 and 14 and dropped to background levels by day 
21 (Fig. 5B). In contrast, the increase in the percentage of CD8+ TAL expressing 
gzmA was less pronounced (p>0.05) in wt mice. The percentages of CD8+ TAL 
expressing gzmB did not differ between wt and IL-4-/- mice on day 14 after challenge 
(Fig. 6C). Together with the dependence of increased resistance of naïve IL-4-/- mice 
against mKSA tumor cells on CD8+ T cells (Fig. 3C) the strong increase in the 
frequency of CD8+ T cells expressing gzmA in IL-4-/- mice suggests that after 
challenge with low doses of mKSA cells naïve IL-4-/- mice generate a CD8+ T cell 
response of some anti-tumor activity leading to prolonged survival of the mice. 
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However, the steep decline in the total numbers (Fig. 6A) and in the percentage of 
gzmA-expressing CD8+ T cells between days 14 and 21 (Fig. 6C) and the delayed 
death of these mice from about day 20 on, indicate that this endogenous T cell 
response is too weak to eradicate the fast growing (cell cycle time about 12h) and 
highly malignant  mKSA tumor cells. 
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+FIG. 4. Primary cytotoxicity of CD8  TAL from Tag-immunized IL-4-/- or wild-type mice at different 
times after challenge.  
(legend on next page) 
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+FIG. 4. Primary cytotoxicity of CD8  TAL from Tag-immunized IL-4-/- or wild-type mice at different 
times after challenge.  
IL-4-/-  or wild-type  mice were immunized on days -14 and –7 by i.p. injection of 10μg TAg and 
challenged i.p. with 10
6 + mKSA cells on day 0. CD8  TAL were immunomagnetically enriched from the 
pooled peritoneal exudate cells of groups of five mice on day 5 (A), day 7 (B), or day 8 (C) after challenge. 
On day 8 CD8+ TAL from a group of wt mice (n=5) that were i.v. treated with 0.5 mg of IL-4 specific mAb 
11B11 on days 0 and 3 after challenge was included . The TAg-specific cytotoxic activity of the CD8+ TAL 
was determined in a standard 4h-chromium release assay using mKSA cells as targets. (D) On day 8 after 
challenge, CD8+ TAL were immunomagnetically enriched from the pooled peritoneal exudate cells of 10 
TAg-immune wild-type mice. TAg-expressing mKSA cells and TAg-negative MethA cells, both derived 
from BALB/c mice and expressing H-2Kd molecules, were used as target cells to prove antigen-specificity 
of the CTL. To prove dependence of cytotoxicity on perforin, in an additional set-up CD8+ effector cells 
were pre-incubated with concanamycin A at a final concentration of 200 nM for 2 h [55].  
+Variable effector : target cell ratios are due to varying yields of CD8  TAL in the different groups. Data 
shown are representative for three comparable experiments. 
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Fig. 5 
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FIG. 5. Characterization of the CD8+ TAL of TAg-immune IL-4-/- and wild type BALB/c mice on day 8 after 
challenge with mKSA cells. 
(legend on next page) 
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FIG. 5. Characterization of the CD8+ TAL of TAg-immune IL-4-/- and wild type BALB/c mice on day 8 after 
challenge with mKSA cells. 
   IL-4-/- (black bars) or wild-type (white bars) mice were immunized on days -14 and –7 by i.p. injection of 10μg 
TAg and challenged i.p. on day 0 with 10
6
 mKSA cells. CD8+ TAL were immunomagnetically enriched from the 
peritoneal exudate cells of individual mice on day 8 after challenge. (A) Numbers of CD8+ TAL recovered from the 
peritoneal cavity. Shown are the mean and standard error for n= 14 wild type and IL-4-/- mice. (B) Surface 
expression level of CD8 determined as mean fluorescence intensity by flow cytometry of CD8+ TAL on day 8 after 
challenge (n=17 for each genotype). (C) Percentage of TAg-specific CD8+ TAL as determined by intracellular 
detection of IFN-γ by flow cytometry in CD8+ TAL after  co-incubation   with TAg-expressing BALB-SV40 fibroblast 
in the presence of Golgi-stop for 6h.. Shown are dot plots from one representative experiment (left panel) and the 
mean and standard error cumulated from 3 independent experiments with  n=9 wild types and n=8 IL-4-/- mice. (D) 
Enumeration of TAg-specific CD8+ TAL by  an IFN-γ-specific Elispot assay (R&D systems). CD8+ TAL were 
incubated at a density of 2x104 5 cells per well with 10  mKSA cells for 24h before developing the assay according 
to the instructions of the manufacturer and enumerating the IFN-γ positive spots by an AID EliSPOT reader 
system ELA 02. Shown are the mean and standard error for n=3 wild type and IL-4-/- mice. The data of IL-4-/- and 
wild type cells in (A) to (D) do not differ statistically significant as determined by Student´s t-test.  (E) Granzyme A 
was detected by flow cytometry after intracellular staining of the cells with a rabbit anti mouse granzyme A serum. 
Shown are representative dot plots (upper panel) and the mean and standard error for n=10 wild type and IL-4-/- 
mice (lower panel). The statistical significance of IL-4-/- versus wild types is p<0.05 according to Student´s t-test. 
(F) Measurement of Granzyme B-expressing cells and of gzmB-specific enzymatic activity in CD8+ TAL on day 8 
after challenge. Granzyme B was detected by flow cytometry after intracellular staining of the cells with the mAb 
GB12 specific for human granzyme B, which was shown to cross-react with murine granzyme B previously [39, 
40]. Shown are representative dot plots (upper panel) the mean and standard error for n=5 wild types and IL-4-/- 
mice (lower left panel). The statistical significance of IL-4-/- versus wild types is p<0.05 according to Student´s t-
test. GzmB-specific enzymatic activity in lysates of CD8+ TAL was determined in a colorimetric assay with the 
substrate N-acetyl-Ile-Glu-Pro-Asp-p-nitroanilide (lower right panel). Shown are representative the mean and 
standard error for n=4 wild type and IL-4-/- mice. The statistical significance of IL-4-/- versus wild type is p<0.05 
according to Student´s t-test. 
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+FIG. 6. Characterization of the CD8  TAL of naive IL-4-/- and wild type BALB/c mice challenged with 103 
mKSA cells. 
   Navie IL-4-/- or wild-type mice were challenged i.p. on day 0 with 10
3
 mKSA cells. CD8+ TAL were 
immunomagnetically enriched from the peritoneal exudate cells of individual mice at the indicated times after 
challenge. (A) Numbers of CD8+ TAL recovered from the peritoneal cavity. Shown are means and standard errors 
(day 8: n=3; day 14: n=6; day 21: n=3). (B) Granzyme A was detected by flow cytometry after intracellular staining 
of the cells with a rabbit anti mouse gzmA serum. Shown are the means and standard errors (day 8 and 21: n=3; 
day 14: n=14). Percentage of  CD8+ TAL expressing gzmB as determined by flow cytometry on day 14 after 
challenge (n=6). 
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3. Results II 
 
3.1. Accelerated rejection of mKSA tumor cells by TAg-immune IL-10-/- mice  
 
   Naïve IL-10-deficient (IL-10-/-) or wt BALB/c mice succumb to i.p. challenge with 
1x106 Simian Virus 40 TAg-expressing mKSA tumor cells between day 15 and 25 
after challenge. In contrast, previous immunization of mice with recombinant TAg 
leads to immunoprotection against the tumor (Supplemental Fig.1). Notably, the 
kinetics of tumor cell elimination from the peritoneal cavity differs markedly between 
TAg-immunized IL-10-/- and wt mice. Within 4 days after challenge, proliferating 
mKSA cells completely vanished among the peritoneal exudate cells of TAg-immune 
IL-10-/- mice. In contrast, wild type mice harbored clearly detectable proliferating 
mKSA cells (Fig. 1A).  
   This rapid kinetics of tumor cell eradication was confirmed by in vivo-
bioluminescence imaging and by immunohistology. mKSA cells stably transduced 
with a lentiviral vector coding for Renilla luciferase rapidly formed tumors in naïve IL-
10-/- and wt mice (Fig. 1B). In TAg-immune IL-10-/- mice, the mKSA cells expanded 
less than in wt mice between days 2 and 4 after challenge.  By day 7 after challenge, 
IL-10-/- mice were almost devoid of abdominal bioluminiscence signals as opposed to 
strong signals over large adbominal areas in wt mice. 
   Histomorphological and immunohistochemical analysis of the abdominal cavity 
revealed knotty and diffuse TAg-positive tumor infiltrates along the visceral 
peritoneum. As early as 2 days post challenge, peritoneal TAg-positive mKSA  tumor 
aggregates in IL-10-/- mice were significantly smaller and less frequent than those in 
wt mice (Fig. 2A-B). On day 4, tumor cell aggregates were only rarely detectable in 
IL-10-/- mice but in wt mice mKSA cells were present in large numbers. On day 6, in 
IL-10-/- mice the few remaining  tumor cells were detectable by immunohistochemistry 
only. Eight days after challenge, only single TAg-expressing mKSA cells were 
detectable along the visceral peritoneum in IL-10-/- mice while tumor nodes were still 
large and frequent in wt mice. 
   In IL-10-/- mice, marked infiltrates of CD8+ lymphocytes were detectable in the 
tumor nodules already on day 4 after challenge while in wt mice noteworthy amounts 
of CD8+ lymphocytes were not detectable before day 8 after challenge (Fig. 3). 
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   Taken together, three independent experimental approaches document a more 
rapid reduction of the tumor load in TAg-immune IL-10-/- mice than in corresponding 
wt controls.   
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Figure 1. Accelerated rejection of mKSA tumor cells by TAg-immunized IL-10-/- BALB/c mice. 
(legend on next page) 
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Figure 1. Accelerated rejection of mKSA tumor cells by TAg-immunized IL-10-/- BALB/c mice. 
   Groups of IL-10-/- and wt BALB/c mice were immunized on days -14 and -7 by i.p. injection of 10μg TAg 
or left untreated. On day 0, i.e. seven days after the second immunization, the mice were challenged i.p. 
with 106 mKSA cells. (A) On days 2 and 4 after challenge, peritoneal exudate cells (PEC) harvested by 
peritoneal lavage were plated in ten-fold serial dilutions. After cultivation for 8 days, the cells were fixed 
and stained with crystal violett before clonal colonies of mKSA cells were counted and expressed as 
mKSA cells per 105 PEC. Shown are cumulative data of two independent experiments as values for 
individual mice (n=8 for all groups except for wild type, day 4 n=7) and means for each group (horizontal 
bars). (B) On day 0, immune or naïve mice were challenged i.p. with 106 mKSA cells stably expressing 
Renilla luciferase. At the indicated days, mice were i. v. injected with the luciferase substrate 
coelenterazine, anesthesized and analyzed by transcutaneous luminescence imaging for the distribution 
and signal strength of bioluminescent mKSA cells. All images were taken with identical instrument settings. 
One representative mouse out of 5 mice per group analyzed in three independent experiments is shown. 
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Figure 2. Immunohistochemical detection of TAg-expressing mKSA tumor cells in intraabdominal 
tissues of TAg-immune mice at various times after challenge.   (legend on next page) 
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Figure 2. Immunohistochemical detection of TAg-expressing mKSA tumor cells in intraabdominal 
tissues of TAg-immune mice at various times after challenge. 
   Groups of IL-10-/- and wt BALB/c mice were immunized as described for Fig. 1. On day 0, immune and 
naive mice were challenged i.p. with 106 mKSA cells. At the indicated days after challenge, intestinal 
organs were removed, fixed and stained with TAg-specific rabbit antiserum R15 according to standard 
procedures. Representative mesenterial segments from (A) wt and (B) IL-10-/- mice are shown as 
overviews (4x magnification) and enlargened views (10x magnification) of the indicated inserts. The 
islands of mKSA tumor cells can be easily recognized by their intense red staining of the nuclei, while 
nuclei of infiltrating immune cells appear blue. To allow assessment of the size of tumor nodes, 
micrographs of sections including the intestinal wall were selected.  
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Figure 3. Immunohistochemical detection of infiltrating CD8+ lymphocytes in intraabdominal tumor 
nodules of TAg-immune mice at various times after challenge. 
   Sections of the samples described in Fig. 2 were stained with CD8-specific mAb according to standard 
procedures. Representative mesenterial segments from wt and IL-10-/- mice are shown (10x 
magnification). Please note on day 12 in IL-10-/- mice the cell-dense areas of reactive mesothelial cells 
(arrows) which must not be mistaken for tumor cell aggregates. Immunohistochemical analysis has been 
done in cooperation with Prof. Dr. med Claudia Wickenhauser, Universitätsklinikum Leibzig. 
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3.2. Absence of TAg-specific CD8+ CTL in the peritoneal cavity of TAg-immune  
       IL-10-/- mice  
 
   To identify the cell type mediating accelerated elimination of mKSA tumor cells from 
TAg-immunized IL-10-/- mice, immunized mice were depleted of CD8+ cells by i.v. 
injection of monoclonal antibodies prior to i.p. challenge with mKSA cells. TAg-
immunized IL-10-/- and wt mice depleted of CD8+ cells succumbed to the tumor with 
similar kinetics, while most immune, but non-depleted mice survived the challenge 
(Fig. 4A). These data suggest that CD8+ T cells mediate the eradication of mKSA 
cells both in IL-10-/- and wt mice. 
   The effector mechanism by which mKSA cells are eradicated in IL-10-/- mice was 
further characterized by using mice double deficient for IL-10 and the cytotoxic 
effector molecule perforin (IL-10-/-/perforin-/-). Despite prior immunization with TAg, IL-
10-/-/perforin-/- as well as perforin-/- mice died as rapidly as naïve mice after challenge 
with mKSA cells (Fig. 4B). Apparently, the TAg-specific protection is dependent on 
perforin as expected. 
   As shown previously in our earlier studies (Zerrahn et al., 1996; Utermöhlen et al., 
1996; Baschuk et al., 2007), cytolytically active CD8+ CTL were detectable among 
the peritoneal exudate cells of TAg-immunized wt mice from day 6 after challenge on 
(Fig. 4C). Surprisingly, CD8+ T cells were mostly absent in the peritoneal cavity of 
TAg-immunized IL-10-/- mice. The few CD8+ T cells recovered from IL-10-/- mice did 
not lyse mKSA cells to a significant degree, regardless whether they were harvested 
on day 4, 6, or 8 after tumor cell challenge. It was conspicuous that lower numbers of 
CD8+ T cells were recovered from IL-10-/- than from wt mice (Fig. 4D). The numbers 
of peritoneal CD8+ T cells specific for mKSA cells were determined by measuring the 
intracellular accumulation of IFN-γ in T cells stimulated with mKSA tumor cells using 
flow cytometry. In IL-10-/- mice lower numbers of tumor-specific CD8+ T cells were 
detectable than in wt mice (Fig. 4E). In light of the accelerated kinetics of tumor cell 
eradication in IL-10-/- mice, the lack of CD8+ T cells with significant TAg-specific 
cytotoxic activity in peritoneal exudates was puzzling. This led to the hypothesis that 
TAg-specific CD8+ CTL reside in some other tissue of IL-10-/- mice.  
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Figure 4. Characterization of the TAg-specific CD8+ T cell response of IL-10-/- and wt mice during 
rejection of i.p. injected mKSA cells.  (legend on next page) 
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Figure 4. Characterization of the TAg-specific CD8+ T cell response of IL-10-/- and wt mice during 
rejection of i.p. injected mKSA cells. 
Groups of mice were immunized twice by i.p. injection of 10µg TAg at a weekly interval. (A) Six days after the 
second immunization, groups of IL-10-/- (n=14) or wt (n=15) mice were treated by i.v. injection of 500 µg CD8-
specific mAb while the control groups (wt: n=15; IL-10-/-: n=10) received no mAb treatment. One day after T cell 
depletion, mice were challenged by i.p. inoculation of 106 mKSA cells. Cumulative data from three independent 
experiments are shown as a Kaplan Meier graph of the survival of mice. (B) Naïve or TAg-immune wt mice, mice 
deficient for perforin (perf-/-), or mice deficient for both IL-10 and perforin (IL-10-/-/perf-/-), were i.p. challenged with 
106 mKSA cells and monitored for tumor-dependent 
death daily. (C) On days 4, 6, or 8 after challenge, CD8+ TAL were immunomagnetically enriched from 
pooled peritoneal exudate cells of 5 mice per group (purity of CD8+ cells >95%). The TAg-specific cytotoxic 
activity of these CD8+ TAL was determined in a standard 4h-chromium release assay using mKSA cells as 
targets. Variable E:T ratios are due to various yields of CD8+ TAL in the groups and are an indicator for the 
low numbers of CD8+ TAL in particular in IL-10-/- mice. Shown is one representative series of cytotoxicity 
assays out of three. (D) Absolute numbers of CD8+ TAL that were harvested by immunomagnetic 
enrichment from PEC of individual mice. Cumulative data of at least 3 experiments per day including 6 to 
15 mice are shown as means and SEM. Statistical significance of the increase of CD8+ TAL: IL-10-/-: day 6 
versus day 2: p>0.05; wt: day 6 versus day 2: p<0.05; day 8 versus day 2: p< 0.001. (E) The CD8+ TAL 
described in (D) were incubated on a confluent layer of mKSA cells for 6 hours and processed according to 
standard procedures for the detection of intracellular IFN-γ by flow cytometry. CD8+ TAL incubated in the 
presence of TAg-negative, H-2d MethA tumor cells did not produce IFN-γ (data not shown).  The number of 
CD8+ TAL per mouse TAg-specifically producing IFN-γ was calculated from the number of CD8+ TAL per 
mouse and the frequency of IFN-γ producing CD8+ TAL. Shown are mean and SEM. Statistical 
significance: d8: wt versus IL-10-/- p=0.056.  
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3.3. Cytotoxicity of TAg-specific CD8+ intestinal intraepithelial lymphocytes in  
       TAg-immunized IL-10-/- mice 
 
   Like conventional CTL, intestinal intraepithelial lymphocytes (IEL) express the CD8+ 
phenotype. One of the hallmarks of CD8+ IEL is their spontaneous high cytotoxicity 
against epithelial tumor cells detectable ex vivo (Roberts et al., 1993). Because 
intestinal CD8+ IEL were shown to exert during viral infection systemic antigen-
specific protection (Corazza et al., 2000), we tested whether IEL contribute to 
antitumoral immunity in IL-10-/- mice.  Intestinal CD8+ IEL harvested from TAg-
immunized IL-10-/- mice on day two after i.p. challenge with mKSA are highly 
cytotoxic against mKSA cells at moderate effector to target ratios, while CD8+ 
intestinal IEL from wt mice do not lyse mKSA cells at all (Fig. 5A). CD8+ intestinal IEL 
prepared from IL-10-/- mice on day 2 after challenge are specific for TAg, because 
they lyse the H2d-positive, TAg-expressing mKSA cells but not the syngeneic, TAg-
negative MethA tumor cells (Suppl. Fig. 2).  
   The frequency of CD8+ intestinal IEL responsive to mKSA cells was determined by 
flow cytometry and ELISpot assays. On day 2 after challenge, about 17% of IL-10-/- 
versus 8% of wt CD8+ intestinal IEL accumulated intracellular IFN-γ after non-specific 
stimulation with PMA/ionomycin (data not shown). In response to specific stimulation 
with mKSA cells almost 2% of IL-10-/- versus about 0.7% of wt CD8+ intestinal IEL 
became positive for IFN-γ (Fig. 5B). The frequency of IL-10-/- CD8+ intestinal IEL 
secreting IFN-γ in response to mKSA cells was about threefold higher than that of wt 
CD8+ intestinal IEL as determined by ELISpot (Fig. 5C).   
   These data show that as early as 2 days after i.p. challenge with mKSA cells in 
TAg-immune IL-10-/- mice the frequency of CD8+ intestinal IEL specifically reacting to 
mKSA cells is at least twofold higher than in wt controls. More importantly, only IL-10-
/- , but not wt CD8+ intestinal IEL are highly cytotoxic against mKSA cells on day 2 
after challenge.  
   Further characterization by flow cytometry revealed that the IEL prepared from IL-
10-/- or wt mice were CD3+ CD8+ T cells (Suppl. Fig. 3A). These CD8+ intestinal IEL 
from IL-10-/- and wt mice did not differ with respect to the frequencies or expression 
levels of surface markers widely used to characterize IEL, i.e. CD44, CD62L, CD69, 
or CD103 (Suppl. Fig. 3B). Moreover, CD8+ IEL from IL-10-/- or wt mice did not differ 
with regard to expression of CD8α, CD8β, TCRα/β, or TCRγ/δ (Suppl. Fig. 3C). 
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Together, CD8+ intestinal IEL from TAg-immune IL-10-/- versus wt mice are 
phenotypically undistinguishable with regard to activation markers or components of 
the TCR complex, but differ functionally in the frequency of TAg-specific cells and 
their TAg-specific cytotoxic activity.  
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Figure 5. Functional ex vivo characterization of the mKSA-specific activity of CD8+ intestinal 
intraepithelial lymphocytes from TAg immunized IL-10-/- and wt mice early after challenge with 
mKSA cells.   (legend on next page) 
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Figure 5. Functional ex vivo characterization of the mKSA-specific activity of CD8+ intestinal 
intraepithelial lymphocytes from TAg immunized IL-10-/- and wt mice early after challenge with 
mKSA cells. 
    Mice were immunized on days -14 and -7 by i.p. injection of 10μg TAg and challenged i.p. with 106 
mKSA on day 0. CD8+ cells were immunomagnetically enriched from intestinal intraepithelial lymphocytes 
of mice at the indicated days after challenge. (A) Primary cytotoxic activity of the CD8+ IEL was determined 
in a 5h 51Cr-release assay against mKSA cells on day 2 after challenge. Shown are the means and SEM of 
cumulative data from 5 independent experiments including 5 IL-10-/- and 7 wt mice. The statistical 
significance was determined for the indicated E:T ratios with Student´s t-test. (B) The frequency of CD8+ 
IEL expressing IFN-γ was determined by flow cytometry after specific stimulation with mKSA target cells. 
Shown are the means and SEM of cumulative data from 2 independent experiments including n=3 mice 
per group. (C) The frequency of CD8+ IEL secreting IFN-γ in response to mKSA cells was determined by 
ELISpot assays according to standard procedures. Shown are the means and SEM of cumulative data 
from 3 independent experiments including n=6 mice per genotype. 
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3.4. Intravenously transferred CD8+ intestinal IEL from TAg-immunized IL-10-/-    
        mice protect naïve wt mice against lethal challenge with mKSA cells 
 
   The in vivo relevance of the ex vivo highly cytotoxic CD8+ intestinal IEL from IL-10-/- 
mice was assessed by adoptive transfer experiments. On day 2 after challenge of 
TAg-immunized mice, CD8+ intestinal IEL were immunomagnetically enriched and 
transferred into naïve wt acceptor mice that were previously challenged with mKSA 
cells. After intravenous transfer of CD8+ intestinal IEL from IL-10-/- donor mice, 89% 
(8 of 9) of naïve acceptor mice survived the challenge with mKSA cells whereas only 
11% (1 of 9) acceptor mice survived that received CD8+ intestinal IEL from wt donors  
(Fig. 6A). To exclude the remote possibility that this significant difference might be 
due to the transfer of contaminating tumor cells among the CD8+ intestinal IEL from 
wt donors, groups of naïve acceptor mice received IEL from donors of either 
genotype without being subsequently challenged. None of these mice died, indicating 
that the preparations of IEL were not contaminated by mKSA cells. Strikingly, neither 
IL-10-/- nor wt CD8+ intestinal IEL protected naïve acceptor mice against challenge 
with mKSA cells when the IEL were transferred by intraperitoneal injection (Fig. 6B). 
   Unlike intestinal CD8+ IEL, adoptively transferred conventional CD8+ T cells 
prepared from tumor-associated lymphocytes (TAL) from TAg-immune IL-10-/- or wt 
mice did not protect naïve recipients against mKSA tumor cells regardless whether 
the CD8+ TAL were transferred i.v. or i.p. (Fig. 6C and D). This underscores the 
outstanding antitumoral effector activity of IL-10-/- CD8+ IEL versus conventional 
CD8+ CTL in vivo.   
   The data suggest that CD8+ intestinal IEL of TAg-immunized IL-10-/- mice not only 
are highly cytotoxic ex vivo, but are also able to protect in vivo naïve acceptor mice 
against mKSA cells.  
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Figure 6. Protection of naïve BALB/c mice against mKSA cells by i.v. transfer of CD8+ IEL from TAg-
immunized IL-10-/- but not from wt mice. 
   IL-10-/- and wt donor mice were immunized on days -14 and -7 by i.p. injection of 10μg TAg and challenged i.p. 
with 106 mKSA cells on day 0. Two days after challenge, CD8+ IEL were prepared and transferred (A) i.v. or (B) 
i.p. at doses of 1x106 cells per mouse into naïve BALB/c recipients that had been challenged i.p. with 103 mKSA 
cells 1 h previously. To exclude that contaminating mKSA cells were transferred with enriched CD8+ IEL, control 
mice received CD8+ IEL but no challenge inoculum of mKSA cells. Shown are cumulative data for each i.v. or i.p. 
transfer from three independent experiments. Kaplan-Meier curves were analyzed for statistical significance by 
log-rank test. 
   Eight days after challenge, CD8+ tumor-associated lymphocytes (TAL) were prepared from peritoneal exudate 
cells and transferred (C) i.v. or (D) i.p. at doses of 1x106 cells per mouse into naïve BALB/c recipients that had 
been challenged i.p. with 103 mKSA cells 1 h previously. Shown are cumulative data of three (C) or two (D) 
independent experiments.  
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3.5. T cell-derived IL-10 is not significantly involved in suppressing TAg-     
        specific CD8+ intestinal IEL 
 
   CD4+ T cells harvested from the peritoneal cavity of TAg-immunized wt mice 
secrete considerable amounts of IL-10 from day 4 after challenge onwards (Fig. 6A), 
raising the question whether T cell-derived IL-10 suppresses the generation of TAg-
specific CD8+ intestinal IEL in wt mice.  
   In mice with a T cell-specific inactivation of the IL-10 gene (IL-10FL/FLCD4-Cre+) 
(Roers wt al., 2004) the tumor load in the peritoneal cavity was similar to that in 
immune IL-10FL/FLCD4-Cre- mice, which were used as wt controls (Fig. 6B). In 
contrast, the tumor load in whole-body IL-10-deficient mice was about 70-fold lower. 
Additionally, only CD8+ intestinal IEL from IL-10-/- mice but not from IL-10FL/FLCD4-
Cre+ mice were highly cytotoxic against mKSA cells (Fig. 6C).  
   The data suggest that T cell-derived IL-10 is not significantly involved in 
suppressing the generation of TAg-specific CD8+ intestinal IEL in mice.  
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Figure 6. Specific deletion of IL-10 in T cells does not result in the generation of TAg-specific CD8+ 
cytotoxic IEL or in the hyperacute rejection of mKSA cells.   (legend on next page) 
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Figure 6. Specific deletion of IL-10 in T cells does not result in the generation of TAg-specific CD8+ 
cytotoxic IEL or in the hyperacute rejection of mKSA cells.  
Groups of wt, IL-10FL/FLCD4-Cre- , IL-10-/- or IL-10FL/FLCD4-Cre+ mice were immunized on days -14 and -7 by 
i.p. injection of 10mg TAg and challenged i.p. with 106 mKSA cells on day 0. (A) CD4+ TAL cells were 
immunomagnetically enriched from peritoneal exudate cells collected from wt mice prior to challenge (day 0; cells 
pooled from 15 mice) or on days 4, 6, 8, or 14 after challenge (pooled from 5 mice per day) and kept at a densitiy 
of 1 x106 cells/ml in complete RPMI medium without any further stimuli for 24h. IL-10 in the cell-free supernatants 
of these cultures were determined by ELISA. Shown are the means and standard error of the mean of two 
independent experiments. (B) The numbers of proliferating mKSA cells recovered from the peritoneal cavity of 
mice on day 4 after challenge were determined as described for Fig. 1. Shown are cumulative data of two 
independent experiments as values for individual mice and means (horizontal bars) for each group. (C) On day 2 
after challenge, cytotoxic activity of CD8+ IEL from IL-10FL/FLCD4-Cre-, IL-10-/- or IL-10FL/FLCD4-Cre+ mice 
was determined with mKSA cells as target cells in chromium release assays. Shown are cumulative data from 
three independent experiments as means and SEM.  
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Suppl. Fig. 1
 
 
 
 
 
 
 
 
Suppl. Fig. 1 
 
 
 
 
 
 
 
 
 
suppl. Figure 1. Survival of TAg-immunized IL-10-/- and wt BALB/c mice after i.p. challenge with mKSA 
tumor cells. 
   Groups of IL-10-/- and wt BALB/c mice were immunized on days -14 and -7 by i.p. injection of 10mg TAg or left 
untreated. On day 0, i.e. seven days after the second immunization, the mice were challenged i.p. with 106 mKSA 
cells. Survival of the mice was monitored daily up to 50 days after challenge.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suppl. Fig. 2. CD8+ IEL prepared from TAg-immune IL-10-/-  mice specifically lyse TAg-expressing 
syngeneic tumor cells. 
    Mice were immunized on days -14 and -7 by i.p. injection of 10mg TAg and challenged i.p. with 106 mKSA on 
day 0. CD8+ cells were immunomagnetically enriched from intestinal intraepithelial lymphocytes of mice at day 2 
after challenge. Specificity of CD8+ IEL for TAg was assessed by using either TAg-negative, H-2d-positve MethA 
tumor cells or TAg-expressing, H-2d-positive mKSA cells as target cells in standard chromium release assays. 
One representative experiment out of three is shown.  
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Suppl. Fig. 3 
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Suppl. Fig. 3. Phenotypic characterization of CD8+ IEL prepared from TAg-immune IL-10-/- and wt mice on 
day 2 after challenge with mKSA cells.  (legend on next page) 
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Suppl. Fig. 3. Phenotypic characterization of CD8+ IEL prepared from TAg-immune IL-10-/- and wt mice on 
day 2 after challenge with mKSA cells.  
    IL-10-/- and wt mice were immunized on days -14 and -7 by i.p. injection of 10mg TAg and challenged i.p. with 
106 mKSA on day 0. Two days after challenge, CD8+ cells were immunomagnetically enriched from IEL and 
analyzed for expression of surface markers and TCR-components. (A) Immunomagnetically enriched IEL are  
CD3+ CD8+ T cells. (B) Expression profile of CD44, CD62L, CD69, or CD103 on CD8+ IEL shown in 
representative histograms for each staining (left panel) and as mean +/- SEM of cumulative data (right panel) from 
3 experiments including measurements from 4 mice per marker. (C) Frequency analysis of the expression of 
CD8a, CD8b, TCRa/b, or TCRg/d by CD8+ IEL. Shown are mean +/- standard errors of cumulative data from 3 
experiments including measurements from 3 to 6 mice per marker.  
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3. Results III 
 
3.1. Murine embryonic stem cells are lysed less efficiently than YAC cells by    
       resting or activated natural killer cells 
 
       We have previously shown that embryonic stem cells (ES cells) are resistant to 
lysis by CD8+ cytotoxic T-lymphocytes due to the expression of SPI-6, the specific 
inhibitor of granzyme B (Abdullah et al., 2007). The present study aims at 
characterizing the interaction between ES cells and natural killer (NK) cells in as the 
second important cytotoxic effectorcell type. For this study CGR8 ES cells, derived 
from H-2b expressing 129Ola/Hsd mice were chosen, because these cells can be 
cultivated in vitro without feeder cells. In contrast to studies using feeder cell 
dependent ES cell lines, the use of CGR8 ES cells precludes any interference of 
feeder cells in immunologic assays. 
NK cells were prepared from C57BL/6 mice, also expressing the MHC class I 
haplotype H2b. NK cells were immunomagnetically enriched from splenic single cell 
suspensions of naïve mice or of mice pre-treated with poly I:C to generate activated 
NK cells. In standard 4h 51Cr-release assays, resting or activated NK cells were used 
as effector cells against CGR8 ES cells. YAC cells, the wildly used murine standard 
target cell for NK cells or allogeneic  BALB/c-SV fibroblasts were used as positive or 
negative control target cells, respectively.  
 
     Resting NK cells lysed ES cells to about 20% at an 50:1 E:T ratio. YAC cells were 
lysed two fold more effective than ES cells. As shown in Fig. 1A ES cells required a 
two fold increased effector : target cell ratio, compared to YAC cells, to be lysed to 
the same degree by naïve NK cells. This equals a two fold reduced susceptibility of 
ES cells to NK cell mediated lysis. In contrast, BALB/c-SV fibroblasts expressing high 
levels of allogeneic MHC class I molecules were lysed to minimal extents by resting 
NK cells.  
Compared to the cytotocix activity NK cells, poly I:C activated NK cells exerted higher 
cytotoxic activity by lysing  ES cells to about 60% and YAC cells to about 80% at an 
100:1 E:T ratio (Fig. 1B). Importantly activated NK cells, lysed ES cells two fold less 
effectively than YAC cells. Embryoid body cells (EB cells) at day five of differentiation 
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were lysed to comparable extends like undifferentiated ES cells by activated NK cells 
(Fig. 1B). 
    To asses the lysis of ES and day 5 EB cells by NK cells activated by a physiologic 
stimulus, NK cells were prepared from mice on day four after intravenous (i.v.) 
infection with the LCM-virus.  Virus induced NK cells lysed undifferentiated ES cells 
and day five EB cells to the same degree as poly I:C activated NK cells. Additionally, 
YAC control cells, were also lysed comparable by  LCMV induced NK cells as by 
poly:IC activated NK cells (Fig. 1C). This result excludes the possibility that the 
reduced lysis of ES and EB cells by resting or poly I:C activated NK cells is due to 
poor activation of NK cells by the non physiological stimulus poly I:C. 
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Fig. 1     ES cells and EB cells are lysed less effectively than YAC cells by resting and activated NK cells 
 
    Resting, poly I:C, or LCMV activated NK cells were prepared from B6 mice. NK cells were immunomagnetically 
enriched from splenic single cell suspensions and used as effector cells against undifferentiated ES cells, day five 
EB cells, YAC cells or Balb/c-SV fibroblasts in a 4 h 51Cr release 
(A) Cytotoxic activity of resting NK cells from naive B6 mice, against ES cells, YAC cells and Balb/c-SV 
fibroblasts.(B) Cytotoxic acivity against ES cells, day five EB cells, YAC cells or Balb/c-SV fibroblasts of NK cells 
activated two days prior to experiment with poly I:C. (C) Cytotoxic activity against ES cells, day five EB cells, YAC 
cells and Balb/c-SV fibroblasts of f NK cells activated four days prior to experiment with LCMV. 
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3.2. Expression of MHC class I molecules by ES and EB cells 
 
      NK cells are triggered by integration of signals from inhibitory and activating 
receptors. Engagement of inhibitory receptors by MHC I molecules on target cells 
blocks early activation signals. Vice versa, lack of MHC class I on target cells results 
in prevailing of activating signals and triggering of cytotoxic activity, which has been 
formulated as the  “missing self hypothesis” of NK cell activation (Ljunggren et al., 
1990). Murine ES cells were reported to be devoid of MHC class I molecules (Tian et 
al., 1997; , Draper et al., 2002 , Drukker et al., 2002; Bonde et al., 2006; Abdullah 
etal., 2007), which was confirmed by flow cytometry for the CGR8 ES cells used in 
this study. After induction of differentiation, MHC I is expressed at low levels by day 
five EB cells, while B6SV fibroblast as positive controls, express high levels of MHC 
class I molecules (Fig.2A). 
     IFNγ enhances the expression of MHC class I molecules in adult (Hobart et al., 
1997; Niederwieser et al.,1988) as well as in embryonic cells that express IFNγ 
receptors on their surface (Li et al., 2004; Hobart et al., 1997). 
 To asses whether IFNγ enhances the level of MHC I expression on the ES and EB 
cells used in this study, the cells were incubated with 20ng/ml IFNγ for 48 hours. IFNγ 
treatment did not enhance MHC class I expression on ES cells. However, a fraction 
of day five EB cells responded to IFNγ with enhanced expression of MHC I, albeit not 
as strong as B6SV fibroblast cells (Fig.2A). The absent or low expression of MHC 
class I molecules on ES and EB cells, respectively, should render these cells ideal 
targets for NK cells. Although EB cells express higher levels of MHC class I 
molecules than ES cells, EB and ES cells were lysed to the same degree by poly I:C 
activated NK cells (Fig. 1B). 
This suggests that expression levels of MHC class I on ES and EB cells might not be 
crucial for the susceptibility of these cells to NK cell mediated lysis. 
To address this point in more detail, ES and day five EB cells were left untreated or 
pre-treated with IFNγ and incubated with poly I:C activated NK cells in  4h standard 
51Cr-release assays. The susceptibility of ES and day five EB cells pre-treated with 
IFNγ was indistinguishable from that of untreated cells (Fig. 2B). These results 
strongly indicate that low levels of surface MHC class I molecules are not a decisive 
trigger for NK cell mediated lysis of ES and EB cells.  
 
 65
                                                                                                                       Results III 
A 
 
 
 
 
 
 
 
 
B 
H-2Kb
C
ou
nt
s
B6SV fibroblasts ES cells Day 5 EB
100 101 102 103 104
FL2-H
0 
   
   
 1
0 
   
   
20
   
   
 3
0 
   
   
40
   
   
 5
0
0 
   
   
 1
0 
   
   
20
   
   
 3
0 
   
   
40
   
   
 5
0
100 101 102 103 104
FL2-H
0 
   
   
 1
0 
   
   
20
   
   
 3
0 
   
   
40
   
   
 5
0
0 
   
   
 1
0 
   
   
20
   
   
 3
0 
   
   
40
   
   
 5
0
100 101 102 103 104
FL2-H
0 
   
   
 1
0 
   
   
20
   
   
 3
0 
   
   
40
   
   
 5
0
0 
   
   
 1
0 
   
   
20
   
   
 3
0 
   
   
40
   
   
 5
0
isotype
w/o IFN-γ
+ IFN-γ isotype
w/o IFN-γ
+ IFN-γ
isotype
w/o IFN-γ
+ IFN-γ
poly I:C activated NK cells
effector : target ratio
0 20 40 60 80 100
%
 s
pe
ci
fic
 ly
si
s
0
20
40
60
80
100
YAC
ES
ES + IFN-γ
d5 EB
d5 EB + IFN-γ
BALB/c-SV
 
 
Fig. 2     Expression of MHC class I molecules on the surface of ES and day five EB cells and influence of    
              pre-treatment of ES cells with IFNγ on susceptibility to NK cell mediated lysis. 
 
    (A) Flow cytometric analysis of MHC class I molecules on the surface of undifferentiated ES cells and day five 
EB cells. B6SV fibroblasts (from H-2b C57BL/6 mice) were used as positive control. To induce expression of 
MHC class I molecules, IFNγ was added to a final concentration of 20ng/ml for 48 h. Single cell suspensions of 
ES or EB cells were stained with the monoclonal antibody specific for H2Kb (clone AF6-88.5, BD Pharmingen) or 
isotype control  antibody. Results were analysed by FACScan and CellQuest software. 
(B) Cytotoxic activity of polyI:C activated NK cells against untreated ES cells, EB cells, YAC cells and Balb/c-SV 
fibroblasts left untreated (white symbols), or with a IFNγ pre-treated ES cells (black symbols). Shown are 
cumulative data of three experiments. 
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3.3. Murine ES cells and EB cells are properly recognized by resting or    
       activated NK cells 
 
       The observation that undifferentiated ES and day five EB cells are lysed less 
effectively than YAC cells by resting or activated NK cells (Fig.1) raised the question, 
whether NK cells do properly recognize ES and EB cells as target cells. To address 
this question the secretion of IFNγ by immunomagnetically enriched resting, poly I:C 
or virus activated  NK cells of C57BL/6 mice in response to ES cells, day five EB 
cells, YAC cells as positive and BALB/cSV fibroblasts as negative control was 
determined. After a 24 h incubation time, IFNγ was measured in the supernatants by 
ELISA, in order to assess the recognition of the target cells by NK cells. Within 24 h, 
resting, poly I:C- or LCM virus- induced NK cells secreted similar high amounts of 
IFNγ in response to either ES cells, EB cells or YAC cells, while in response to 
BALB/cSV fibroblasts only background levels of IFNγ were secreted. These results 
indicate that NK cells recognize ES cells or day five EB cells as well as YAC cells. 
However, despite proper recognition, NK cells do not lyse ES and day five EB cells 
as effectively as YAC cells. 
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Fig. 3     Secretion of IFNγ by NK cells in response to ES and EB cells 
 
    NK cells from naive, poly I:C or LCMV activated mice were immunomagnetically enriched from splenic single 
cell suspensions and used as effector cells. The effector cells were incubated with undifferentiated ES cells, day 
five EB cells, or YAC cells  (positive control) and Balb/c-SV fibroblasts (negative control). After 24 hours 
supernatants of the cultures were collected and IFNγ was quantified by ELISA. 
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3.4. Lysis of ES cells is perforin dependent 
 
       The discrepancy between full recognition but reduced cytolysis of ES and EB 
cells by resting or activated NK cells raised the question, whether ES cells might be 
resistant to the cytotoxic effector molecules used by NK cells. NK cells induce cell 
death via two distinct pathways: secretion of cytotoxic granules or binding and 
oligomerization of death receptors. The cytotoxic granules contain several cytotoxic 
effector molecules, including the pore-forming protein perforin and granzymes. 
Perforin is indispensable for the induction of target cell lysis (Trapani et al., 2002; 
Voskoboinik  et al., 2006). 
To determine if lysis of ES and EB cells is perforin-dependent, activated NK cells 
from perforin deficient mice (perforin-/-) were used as effector cells in cytotoxicity 
assays against ES cells, YAC cells or BALB/cSV fibroblasts. Neither YAC cells nor 
ES cells were lysed by NK cells from perforin-/- (Fig. 4), suggesting that the lysis of 
ES cells by NK cells relies on the perforin dependent cytotoxic pathway.  
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Fig. 4   Lysis of ES is perforin dependent 
 
   C57BL/6 mice and C57BL/6 perforin-/- mice were left untreated or activated by i.p. injection of poly I:C two days 
prior to the experiment. Resting and activated NK cells were immunomagnetically enriched from splenic single 
cell suspensions and used as effector cells in a 4h 51Cr release assay against ES cells. YAC cells were used as 
positive controls and Balb/cSV fibroblasts as negative controls. 
Lysis of ES cells, YAC cells and Balb/cSV fibroblasts by activated NK cells from C57BL/6 (white symbols) and or 
C57BL/6 perforin-/- mice (black symbols). 
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3.5. Expression of cathepsin B and Serpin 6 does not contribute to reduced     
       susceptibility of ES cells to NK cell mediated lysis 
 
      We have previously shown that ES and EB cells express Cathepsin B, the 
specific inhibitor of perforin (Abdullah et al., 2007). To test whether Cathepsin B 
might be involved in the reduced susceptibility of ES cells to NK cell mediated lysis, 
ES cells were pre-treated with the specific inhibitor of Cathepsin B, CA074, for 16 h 
prior to experiment. Inhibition of Cathepsin B did not render ES cells significantly 
more susceptible to  lysis by resting (Fig. 5 A) or polyI:C activated (Fig. 5 B) NK 
cells. 
In addition to Cathepsin B, ES and EB cells express high levels of SPI-6, the specific 
inhibitor of Granzyme B. Knock down of SPI-6 expression by specific shRNA 
rendered ES cells fully susceptible to lysis by antigen-specific CD8+ CTL (34). 
To determine whether low susceptibility of ES cells for NK cell mediated lysis is 
mediated by SPI-6, ES cells stably expressing SPI-6 specific shRNA (SPI-6-shRNA) 
or scrambled shRNA (scrRNA) were used as target cells for resting or activated NK 
cells in  51Cr release assays. Knock down of SPI-6 did not enhance the susceptibility 
of ES cells to lysis either by resting (Fig. 5C) or by activated (Fig. 5D) NK cells. The 
scr ES control target cells, were lysed to the same degree as SPI-6 knock down ES 
cells (Fig. 5C, D). 
Even combined inhibition of Cathepsin B and SPI-6 knock down did not enhance 
lysis of ES cells by either resting (Fig. 5E) or activated (Fig. 5F) NK cells.  
Thus, although expressed at high levels by ES cells, neither SPI-6 nor Cathepsin B 
do contribute to the low susceptibility of ES cells for lysis by NK cells. 
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Fig. 5  Expression of cathepsin B and Serpin 6 does not contribute to reduced susceptibility of ES cells     
             for NK cell  mediated lysis.  (legend on next page)     
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         Fig. 5  Expression of cathepsin B and Serpin 6 does not contribute to reduced susceptibility of ES cells    
                for NK cell mediated lysis 
 
    C57BL/6 mice were left untreated or activated by i.p. injection of poly I:C two days prior to experiment. Resting 
and activated NK cells were immunomagnetically enriched from splenic single cell suspensions and used as 
effector cells in a 4h 51Cr release assay against target cells. 
Resting (A, C, E) or poly I:C activated (B, D, F) NK cells were used against the following target cells: 
(A, B) ES cells pre-treated with 10μM CA074 16 h prior to experiment (black symbol), untreated (white symbols) 
or of YAC cells or Balb/cSV fibroblasts.  
(C, D) shSPI-6 ES cells, scrSPI-6 control cells (black symbols), wild type (wt) ES cells, YAC cells and Balb/cSV 
fibroblasts (white symbols). 
(E, F) shSPI-6 ES cells, wt ES cells pre-treated with 10μM CA074 16 h prior to experiment (black symbols) and 
untreated control cells (white symbols) 
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3.6. Resting and activated NK cells express Granzyme M 
 
    Since both, NK cells and CTL, use cytotoxic granules to kill target cells, it was 
surprising that high level expression of Cathepsin B and SPI-6 apparently does not 
contribute to the low susceptibility of ES cells to NK cells. However, despite 
similarities in their cytotoxic effector molecules, NK cells and CTL differ considerably 
in the usage of specific granzymes as cytotoxic effector molecules (Sayers et al., 
2001; Smyth et al.,1995). Most prominently, NK cells express high levels of 
granzyme M (Sayers et al., 2008; Chowdhury,et al., 2008; Janice et al., 2004). 
Granzyme M is involved in cytotoxicity although its exact mode of action has not yet 
been elucidated (Chowdhury,et al., 2008; Janice et al., 2004). The resting and 
activated NK cells used in this study contain large amounts of granzyme M specific 
mRNA and granzyme M specific enzymatic activity, as determined by quantitative 
real time PCR and granzyme M-specific substrate cleavage (Fig. 6A,B). 
Resting NK cells and activated CD8+ CTL harvested from mice on day eight post 
LCM virus infection express comparable low amounts of granzyme M-specific mRNA, 
while poly I:C activated NK cells express four-fold increased levels of granzyme M- 
specific mRNA.  The granzyme M enzymatic activity of resting NK cells is already 
higher than that of CD8+ CTL, and in activated NK cells even higher activities are 
detected. Although the exact role of granzyme M in NK cell mediated cytotoxicity is 
not yet known, differential expression and use of granzyme M by NK cells and CTL 
might be responsible for the differential susceptibility of ES cells to the two cytotoxic 
effector cell types. 
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Fig. 6   Expression of granzyme M in resting and activated NK cells  
 
    Resting and activated NK cells were prepared from naïve or poly I:C activated C57BL/6 mice and were 
immunomagnetically enriched from spleens. 
(A) Expression of mRNA coding for murine granzyme M was determined by real time PCR in resting NK cells, 
poly I:C activated NK cells, CD8+ CTL from day 8 LCM virus-infected C57BL/6 mice and B6SV fibroblasts.  
(B) Granzyme M enzymatic activity of lysates from 5x105 resting NK cells, poly I:C activated NK cells, CD8+ CTL 
from day 8 LCM virus-infected C57BL/6 mice and B6SV fibroblasts by cleavage of the chromogenic substrate 
Boc-Ala-Ala-Met-SBzl .  
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3.7 Expression of  the Serine Protease Inhibitor Involved in Cytotoxic  
      Inhibition (SPI-CI), a specific inhibitor of granzyme M 
 
        The murine serine protease inhibitor involved in cytotoxic inhibition (SPI-CI) is a 
chymotrypsin-specific inhibitor of granzyme M (Bots et al., 2005), comparable to SPI-
6 as the specific inhibitor of granzyme B. SPI-CI is expressed by cytotoxic effector 
cells, especially by NK cells. Furthermore, SPI-CI is highly expressed in immune-
privileged sites e.g. placenta, testis and brain (Bots et al., 2005).  
Remarkably, SPI-CI specific mRNA is expressed in ES cells, albeit at lower levels 
than in resting or activated NK cells (Fig. 7).   
To determine, whether SPI-CI contributes to the reduced susceptibility of ES cells for 
NK cell mediated-cytotoxicity, SPI-CI was down-regulated by RNA interference in ES 
cells. Effective down regulation of SPI-CI mRNA was achieved with a Lentiviral 
vector expressing SPI-CI specific shRNA (shSPI-CI). Transduction of ES cells with 
this shRNA lenti-virus significantly reduced the expression of SPI-CI mRNA to about 
15% of untreated control cells (Fig.8). In ES cells transduced with a control vector 
coding for a scrambled sequence (scrSPI-CI), expression of  SPI-CI was almost not 
effected. The influence of SPI-CI on the susceptibility of ES cells for the cytotoxicity 
of NK cells was assessed by using  shSPI-CI ES cells as target for NK cells. 
shSPI-CI ES cells were lysed by, resting (Fig. 9A) and activated (Fig. 9B) NK cells, 
as effectively as YAC cells, while wt ES cells or scrSPI-CI ES cells were less 
susceptible to lysis by resting and activated NK cells. This result indicates that SPI-CI 
partially protects ES cells against lysis by NK cells. 
To elucidate whether SPI-CI and SPI-6 cooperate in the protection of ES cells 
against NK cell mediated lysis, wt ES cells, ES cells expressing specific shRNA for 
SPI-C,I or SPI-6, or combined down regulation of SPI-CI and SPI-6 (shSPI-6/SPI-CI) 
were used as target cells in  4h standard 51Cr release assays. ES cells that are 
deficient for both serpins were lysed by resting (Fig. 10A) and activated (Fig. 10B) 
NK cells comparable to ES cells expressing specific shRNA for SPI-CI, exclusively. 
Thus, the combined knock down of SPI-CI and SPI-6 was not more effective than the 
single knock down of SPI-CI. Therefore, these results indicate that SPI-CI plays a 
critical role in the reduced susceptibility of ES cells for NK cell mediated lysis, while 
SPI-6 does not contribute. 
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Fig. 7     ES cells express SPI-CI, the specific inhibitor of granzyme M 
 
   Expression of mRNA coding for murine SPI-CI was determined by real time PCR in undifferentiated CGR8 ES 
cells, resting NK cells, polyI:C activated NK cells, B6SV fibroblasts, placenta and CD8+ CTL from day 8 LCM 
virus-infected C57BL/6 mice. Expression levels were normalized to GAPDH. 
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 Fig. 8   Down regulation of SPI-CI on mRNA level by specific shRNA 
 
   Quantification of SPI-CI mRNA in CGR8 ES cells after transduction with vectors expressing shRNA targeting 
the specific region of murine SPI-CI (SPI-CI shRNA), or a non-specific scrambled shRNA (scr. shSPI-CI) after 
selection with blasticidin and expansion of single cell clones . The expression level was normalized to the level 
measured in non-treated control cells. 
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Fig. 9   SPI-CI partially protects ES cells against cytolysis by resting or activated NK cells 
 
   C57BL/6 mice were left untreated or were activated i.p. with poly I:C two days prior to experiment. Resting and 
activated NK cells were immunomagnetically enriched from splenic single cell suspensions and used as effector 
cells in a 4h 51Cr release assay against target cells. 
(A) Susceptibility of shSPI-CI ES cells, scrSPI-CI control cells, wt ES cells and YAC cells to resting NK cells from 
naïve C57BL/6.  
(B) Susceptibility of shSPI-CI ES cells,  scrSPI-CI control cells, wt ES cells and YAC cells  to polyI:C activated NK 
cells from B57BL/6. Shown are the cumulative data of three experiments. 
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Fig. 10    SPI-CI and SPI-6 do not cooperate in the protection of ES cells from NK cell mediated lysis 
 
   C57BL/6 mice were left untreated or activated i.p. with poly I:C two days prior to experiment. Resting and 
activated NK cells were immunomagnetically enriched from splenic single cell suspensions and used as effector 
cells in a 4h 51Cr release assay against target cells. 
(A) Susceptibility of shSPI-CI ES cells, shSPI-6 ES cells, scrSPI-CI control cells, wt ES cells, YAC cells and 
shSPI-6/SPI-CI cells  to resting NK cells. 
 (white symbols) to resting NK cells from naïve B57BL/6.  
(B) Susceptibility of shSPI-CI ES cells, shSPI-6 ES cells, scrSPI-CI control cells, wt ES cells, YAC cells and 
shSPI-6/SPI-CI cells to polyI:C activated NK cells.  
Shown are the cumulative data of three experiments. 
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3.8. SPI-CI protects ES cells from NK-cell mediated lysis in vivo 
 
     SPI-CI reduces susceptibility of ES cells for NK cell mediated lysis in vitro. 
The effects of SPI-CI on the susceptibility of ES cells to NK cells were assessed in 
vivo by monitoring the accumulation of PKH labelled wild type ES cells, shSPI-6 ES 
cells, shSPI-CI ES cells, shSPI-6/SPI-CI cells, scrambled control ES cells or YAC 
cells in the spleens. Following i.v. inoculation of 1x107 cells, the numbers of 
fluorescent cells accumulating in the spleens of naïve or poly I:C pre-treated mice 
were determined after 30 minutes and 4 hours. Within 30 minutes after injection 
about 1x105 to 2x105 fluorescent cells were detectable per spleen, regardless 
whether SPI-CI or SPI-6 were expressed or not. By four hours after inoculation, 
numbers of wild type and scrambled shRNA control ES cells in the spleens increased 
up to 8x105 cells per spleen, while the numbers of SPI-CI shRNA ES cells remained 
at about the level of 30 minutes (Fig. 11A). SPI-6 shRNA cells accumulated as well 
as wt control cells, while SPI-6/SPI-CI double knock down cells behaved like SPI-CI 
shRNA cells. YAC cells were at 30 minutes and 4 hours after inoculation only 
detectable in minimal numbers below 0,5x105 per spleen. 
In vitro, ES cells were more susceptible to lysis by activated NK cells than by resting 
NK cells. By monitoring the accumulation of fluorescent cells in poly I:C pre-treated 
mice, it was assessed whether SPI-CI influences the susceptibility of ES cells for the 
cytotoxicity of activated NK cells. Similar to the observations in naïve mice, wt ES 
cells accumulated in the spleens of poly I:C treated mice between 30 minutes and 4 
hours after injection of the cells, albeit the increase was lower than in naïve mice 
(Fig. 11B). In contrast, after 4 hours the number of SPI-CI shRNA ES cells even 
decreased compared to 30 minutes. 
The decreased accumulation of shSPI-CI ES cells in naïve or poly I:C treated mice 
might be due to either altered migration of the cells within the acceptor mice or to 
destruction of the cells by NK cells. To differentiate between these two explanations 
the above described experiments were performed in mice with an impaired granule 
mediated cytotoxicity due to inactivation of the perforin gene (perforin-/-). In sharp 
contrast to wt acceptor mice, in perforin-/- mice shSPI-CI ES cells or as well  control 
ES cells, accumulated to high numbers in the spleens within 4 hours after injection 
(Fig. 11C). This suggests that the failure of shSPI-CI ES cells to accumulate in 
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spleens of wt mice is due to the elimination of these cells by granule mediated 
cytotoxicity. 
To confirm these findings, we assessed the susceptibility of these cells in beige mice. 
Beige mice are profoundly deficient for NK cells and CTL mediated lysis (50) and are 
an accepted model to examine the role of NK cells in vivo. Like in perforin -/-mice, and 
in contrast to wt mice, shSPI-CI ES cells or as well  control ES cells accumulated to 
high numbers in the spleens after 4 hours (Fig. 11D). The high amounts of YAC cells 
in the spleens of beige mice after 4 hours suggests that the susceptibility of shSPI-CI 
ES cells is dependent on NK cells. 
These in vivo results suggest, that in line with the in vitro data, SPI-CI protects ES 
cells in vivo from perforin dependent NK cell mediated lysis. 
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Fig. 11   SPI-CI protects ES cells from NK-cell mediated lysis in vivo. 
(Legend on page 81) 
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Fig. 11   SPI-CI protects ES cells from NK-cell mediated lysis in vivo. (legend on next page) 
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Fig. 11   SPI-CI protects ES cells from NK-cell mediated lysis in vivo 
 
   WT ES cells, shSPI-6 ES cells, shSPI-CI ES cells, shSPI-6/SPI-CI cells,  scrSPI-CI control cells and YAC cells 
were labeled with PKH. 1x107 of PKH labeled cells were i.v. inoculated into naïve or two day prior to experiment 
poly I:C activated C57BL/6 mice. 30 minutes and 4 hours later the total number of living fluorescent cells per 
spleen was ascertained by FACS-Analysis. Total number of inoculated, fluorescent cells in the spleens of: (A) 
naïve C57BL/6 mice, (B) poly I:C activated C57BL/6 mice, (C) naïve perforin -/- mice and (D) naïve beige mice. 
Every bar represents a minimum of  four individuals. 
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3.9. Expression of SPI-CI contributes to the tumorigenicity of ES cells in vivo  
 
     After having shown the relevance of SPI-CI expression for acute resistance of ES 
cells to elimination by NK cell mediated cytotoxicity in vivo for up to four hours, long 
term effects of SPI-CI remained to be evaluated. To this end, the contribution of SPI-
CI to the capacity of ES cells to form teratomas in immuno-competent syngeneic 
hosts was assessed. Following subcutaneous (s.c.) inoculation of 2x106 wild type ES 
cells and scrambled control ES cells, teratomas were detectable from about day 
seven and grew rapidly with similar kinetics. In contrast, SPI-CI knock down ES cells 
caused only in 60 % of the recipients slow growing teratomas, measuring by day 27 
below 2 mm in diameter as opposed to 10 mm resulting from wt ES cells (Fig. 12A, 
B). These results indicate that SPI-CI contributes to the tumorigenicity of ES cells  in 
syngeneic immuno-competent hosts in vivo. 
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Fig. 12   Reduced in vivo tumorigenicity of ES cells deficient for SPI-CI  
 
   2x106  shSPI-CI  ES cells, shSPI-6/SPI-CI ES cells (black symbols) wt ES cells, shSPI-6 ES cells and scrambled 
control ES cells (white symbols) were injected subcutaneously into the neck of complete syngeneic male 129/Ola 
Hsd mice. (A,B) The tumor size was recorded every second day using linear callipers. The tumor growth of the 
individual groups is shown 
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4. Discussion 
 
 
    In many animal models effective tumor-specific immunotherapy has been archived 
(Blattman and Greenberg, 2004). However, success in clinically applied tumor-
immunotherapy has been rather limited. Depending on the specific situation this 
might be due to limited strength or duration of the immune response, or to tumor cells 
evading from or even counterattack against the immune system (Gabriel et al., 2006; 
Siqing et al ., 2006; Qiang et al., 2001; Melief 2008, Ochsenbein, 2002). From these 
experiences can be concluded that chances for effective and reliable immunotherapy 
of tumors depend on a thoroughly insight into the interactions between tumors and 
the immune system in the respective microenvironment during each single phase of 
this immune response. By detailed knowledge of the interaction of specific immune 
cells, of their recruitment into the tumor site, and of the delivery of their effector 
functions. It should  be possible to further enhance desired and to block inhibitory 
immuno-regulatory mechanisms. In this project we revealed three quantitatively 
different approaches to enhance the effectiveness of tumor specific immune 
responses. These approaches are: (i) the inhibition of IL-4 even during the active 
tumor effector phase, resulting in enhanced cytotoxic activity of CD8+ CTL. (ii) The 
inhibition of IL-10 during i.p. immunization and i.p. tumor-challenge, resulting in a 
shift from conventional CD8+ CTL to more potent tumor-specific CD8+ IEL, and (iii) 
the down regulation of SPI-CI in tumor stem cells in order to increase their 
susceptibility for cytotoxic NK cells. 
These three immuno-regulatory aspects of tumor-specific immunotherapy will be 
consecutively discussed below.   
 
 
4.I.  Interleukin-4 impairs granzyme-mediated cytotoxicity of Simian virus 40     
        large tumor antigen-specific CTL in BALB/c mice 
 
     IL-4 is a key cytokine regulating the induction and differentiation of T helper cell 
subsets (Seder at al., 1994; Murphy et al., 2002; Agnello et al., 2004). IL-4 generally 
supports humoral immune responses and suppresses cellular immunity. 
Nevertheless, both, supportive or inhibitory effects of IL-4 upon CD8+ T cells have 
been reported (Utermöhlen et al., 2001; J. Zerrahn et al., 1996, Miller et al., 1990; 
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Erard et al., 1993; M. Croft et al., 1994; Noble et al., 1995; Moran et al., 1996; 
Aleman et al., 2002; Bright et al 1996; Gooding et al., 1977; Knowles et al., 1979; N. 
Kienzle et al 2002, 2005; Schuler et al., 2001, 1999). In this study we analyzed the 
influence of endogenous IL-4 on a CTL response against a notoriously weakly 
immunogenic tumor antigen.   
BALB/c mice are considered to be low- or even non-responders with respect to the 
generation of SV40 TAg-specific CTL, while C57BL/6 mice mount a strong TAg-
specific CTL response (Bright et al., 1996, 1995; Gooding et al., 1977; Knowles et al., 
1977; Newmaste et al., 1998; Schirmbeck et al., 1996; Tevethia etal., 1990). We 
previously detected a small population of highly active TAg-specific CD8+ CTL in the 
peritoneal cavity of TAg-immunized BALB/c mice challenged i.p. with TAg-expressing 
mKSA tumor cells (Zerrahn et al., 1996; Utermöhlen et al., 2001), thereby providing 
us with a system for testing CTL activity induced by this very weakly immunogenic 
antigen. 
   Our finding that CD4+ TAL secrete IL-4 during TAg-specific rejection of mKSA cells 
was somewhat unexpected, as we had already reported that CD4+ TAL secrete the 
prototypic Th1 cytokines IL-2 and IFN-γ (Bright et al., 1996). Thus the tumor site at 
the same time harbors CD4+ T cells secreting antagonistic cytokines, namely IL-4 
and IFN-γ. Furthermore, it had been published that the cytokine profile in TAg-
immune BALB/c mice is a typical TH1 profile (Bright et al., 1995). Specifically, Bright 
and colleagues detected the Th1 factors IL-2 and IFN-γ, but neither IL-4 nor IL-5. 
However, this apparent discrepancy can be easily explained by the different assay 
conditions applied. We studied cytokine secretion by CD4+ TAL enriched from the 
peritoneal cavity during the acute rejection phase of mKSA cells without any 
stimulation in vitro, while these authors investigated the cytokine profile of crude 
spleen lymphocyte preparations from TAg-immunized mice after re-stimulation with 
TAg in vitro. 
   The decisive question about the effects of any given cytokine during tumor-specific 
immune responses is whether this cytokine is necessary, beneficial, futile, or even 
detrimental for the outcome of tumor cell elimination. In our system, TAg-immunized 
IL4-/- as well as wild-type mice survived a challenge with 106 viable mKSA cells, 
equalling the ten thousand-fold LD50 of these tumor cells in naïve BALB/c mice, 
without developing any signs of tumor growth. Additionally, the kinetics of tumor cell 
elimination was similar in wt and IL-4-/- mice. These data clearly indicate that IL-4 is 
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not required for an effective rejection of the highly malignant mKSA tumor cells in 
immunized mice. However, a significant gain in survival time of naïve IL-4-/- mice over 
wild-type controls challenged with low doses of 103 mKSA cells was observed. CD8+ 
TAL harvested on days 8, 14, or 21 after challenge of naïve wt or IL-4-/- mice did not 
exert significant TAg-specific cytotoxic activity in vitro. However, increases in both the 
total numbers of CD8+ TAL and in the percentage of gzmA-expressing CD8+ TAL 
within the peritoneal cavity of wt and IL-4-/- mice at day 14 after challenge suggest 
that mKSA cells induce a T cell response in naïve mice of both genotypes. 
Remarkably, in IL-4-/- mice the increase in gzmA-expressing CD8+ TAL was much 
more pronounced than in wt controls. Moreover, depletion of naive IL-4-/- mice prior to 
challenge abolished their prolonged survival time while the shorter survival time of wt 
mice was not further reduced by depletion of CD8+ T cells. These in vivo data 
strongly indicate that the absence of IL-4 allows the generation of a quite effective 
mKSA tumor-specific CD8+ T cells response in naïve mice. Unfortunately, this T cell 
response apparently becomes insufficient for sustained control of the tumor as 
indicated by the steep decline in the numbers of total as well as gzmA-expressing 
CD8+ T cells between days 14 and 21 after challenge. It remains to be elucidated 
wether the CD8+ T cells are simply diluted out by bleeding into the peritoneal cavity 
from vessels eroded by mKSA cells. Alternatively, a more specific mechanism might 
be at work, e.g. the exhaustion of the small numbers of CD8+ T cells facing the 
growing tumor load. This mechanism has been observed both in chronic virus 
infections and in tumor systems (Gallimore et al., 1998; Klein et al., 2003). A better 
understanding of these mechanisms might provide means to enhance and support 
the endogenous T cell response so that more effective and sustained tumor cell 
control can be achieved. A recent report by Kelso and colleagues indicates that direct 
effects of IL-4 on the effector functions of tumor specific CTL in vivo may be quite 
common (Olver et al., 2006). This group observed that transgenic expression of IL-4 
by P815 tumor cells led to a reduced clearance of this tumor and to a deviated 
cytokine and granzyme profile of tumor associated CD8+ T cells. In our system, the 
IL-4 produced by CD4+ T cells at the tumor site in wt mice does not result in the 
generation of CD8+ T cells producing IL-4 themselves. This might be due to the lower 
amounts of IL-4 secreted by endogenous CD4+ T cells as compared to transgenic 
tumor cells. 
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   In search for the mechanism by which IL-4 impairs TAg-specific resistance against 
mKSA tumor cells, a suppressive effect of IL-4 on the TAg-specific CD8+ CTL 
response was observed. Thus, the cytotoxic activity of CD8+ TAL was significantly 
enhanced in TAg-immune IL-4-/- BALB/c mice after challenge with mKSA cells as 
compared to wild type controls. In addition to the primary ex vivo CTL response 
during tumor cell rejection, also the secondary response of CTL from spleens of TAg-
immunized and mKSA-challenged mice restimulated in vitro was significantly 
enhanced (data not shown). This suggests that in this system the effects of IL-4 are 
imprinted on the effector properties of CTL during the primary challenge phase.  
   Concerning the mechanism of the inhibitory effect of IL-4 in the mKSA system, we 
found that in IL-4-/- mice a significantly enhanced proportion of the CD8+ TAL express 
the cytotoxic effector molecules granzyme A and B during rejection of mKSA tumor 
cells as compared to wt mice. More importantly, the gzmB-specific enzymatic activity 
in the lysates of IL-4-/- CD8+ TAL was significantly increased. As granzyme A and B 
are only  expressed by mature CD8+ CTL, these findings indicate that IL-4 inhibits the 
maturation of the cytotoxic effector function of CD8+ T cells directly. This conclusion 
is further supported by our finding that in IL4-/- mice neither the overall number of 
CD8+ TAL, nor the proportion of CD8+ TAL specific for TAg, as assessed by 
intracellular accumulation as well as secretion of IFN-γ in CD8+ TAL stimulated with 
TAg-expressing target cells, was increased. IL-4 thus does not inhibit the proliferation 
of antigen-specific CD8+ TAL in this system. Direct effects of IL-4 on CD8+ T cells in 
vitro have been recently described by Kelso and colleagues (Kienzle et al., 2002, 
2004, 2005). In a series of elegant studies these authors showed that stimulation of 
naïve CD8+ T cells by immobilized CD3-, CD8-, and CD11a-specific mAb in the 
presence of IL-4 resulted in a gradual loss of CD8 expression and in reduced levels 
of perforin and granzyme mRNA, accompanied by reduced cytolytic activity. In our 
system, the expression levels of CD8 were not reduced in IL-4-competent wt mice. 
Nevertheless, our data further expand the findings reported by Kelso´s group to the 
in vivo situation by demonstrating that endogenous IL-4 in vivo has a comparable 
inhibitory effect on the expression of cytotoxic effector molecules by CD8+ T cells. 
   However, when IL-4 acts indirectly on CD8+ CTL, e.g. via its effects on the 
maturation of DC, a different picture is obtained. Blankenstein and colleagues 
(Schuler et al.,1999, 2002) reported that establishment of tumor specific immunity 
against a mammary adenocarcinoma and a colon carcinoma was severely impaired 
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in IL-4-/- mice. By using IL-4-/- and IL-4 receptor-/- mice in adoptive transfer 
experiments, they showed that in their system IL-4 is produced by CD8+ T cells and 
contributes to the activation of DC, i.e. is effective during the initiation phase of the 
immune response. Thus, in different systems IL-4 can act either indirectly during the 
initiation phase, or directly during the effector phase of a CTL response, thereby 
leading to diverse effects in different systems.  
   The observation of a CD8+ T cell-dependent gain of survival time of IL-4-/- mice 
challenged with low doses of mKSA cells suggests that these mice spontaneously 
mount a tumor-specific T cell response. However, this T cell response is insufficient 
to eradicate the tumor cells.  In patients, CTL responses against tumor antigens also 
are usually rather weak, regardless of whether the CTL were elicited spontaneously 
or by immunization with specific vaccines. Our observations may stimulate studies 
aimed at enhancing the activity of tumor antigen-specific CD8+ CTL by eliminating 
the effects of IL-4. This approach seems rather promising, since in our system both 
the complete lifelong absence of IL-4, as well as the neutralization of IL-4 by specific 
mAb during the effector phase of tumor rejection resulted in comparably enhanced 
TAg-specific CTL activity. The data show promising prospects to interfere with IL-4, 
e. g. by mAb or soluble IL-4 receptor, as a potent modality to enhance and prolong 
CTL responses against tumor-specific antigens in immunotherapeutic treatment of 
cancer.  
 
 
4.II. Highly effective tumor antigen-specific cytotoxicity of intraepithelial    
       lymphocytes unfolded in interleukin-10-deficient mice 
 
   IL-10 suppresses cellular immune responses in many systems (reviewed in 
Montufar-Solis et al., 2007 ), but IL-10 also enhances CD8+ T cell responses in some 
instances (Chen et al., 1991; Giovarelli et al., 1995; Santin et al., 2000; Fujii et al., 
2001). In this light, the effect of IL-10 on the rejection of i.p. injected, TAg-expressing 
mKSA tumor cells by TAg-immunized BALB/c mice appeared rather unpredictable.  
   We observed that IL-10 is not required by TAg-immunized BALB/c mice to mount a 
protective immune response against a lethal challenge inoculum of mKSA tumor 
cells. On the contrary, IL-10-/- mice rejected mKSA cells with accelerated kinetics. 
These data thus suggested that IL-10 suppresses the TAg-specific immune response 
by which wt mice reject mKSA cells.  
 88
                                                                                                                      Discussion  
   Detailed analysis revealed, that the lack of IL-10 does not simply result in a 
quantitatively enhanced, but rather in a qualitatively different immune response. 
Instead of generating intraperitoneal CD8+ lymphocytes with an enhanced cytotoxic 
activity as observed in IL-4-/- mice (Baschuk et al.,2007), IL-10-/- mice were devoid of 
CD8+ T cells with TAg-specific cytotoxic actitivity in the peritoneal cavity at any time 
after challenge. This functional shortage was accompanied by a very limited increase 
of the absolute numbers of intraperitoneal CD8+ lymphocytes in IL-10-/- as compared 
to wt mice. These observations could be explained as a consequence of the early 
elimination of mKSA cells from the peritoneal cavity of IL-10-/- mice, i.e. a reduced 
antigenic stimulus preventing the maturation and/or recruitment of antigen-specific 
CD8+ T cells to this site.  
   Although CD8+ CTL specific for mKSA cells were not detectable in the peritoneal 
cavity of IL-10-/- mice, CD8+ T cells were identified as critically required for rejection 
of mKSA cells in these mice by depletion of CD8+ T cells with CD8-specific mAb. 
Anatomical proximity to the site of tumor cell inoculation led us to hypothesize that 
CD8+ intestinal intraepithelial lymphocytes (IEL) may be the effector cell population 
that mediates accelerated rejection of mKSA tumor cells in IL-10-/- mice.  
Intestinal IEL are heterogeneous with respect to their phenotype, development and 
function (reviewed in Cheroutre 2005). The most typical common feature of intestinal 
IEL is their particular effector memory phenotype for which terms like “activated yet 
resting” (Cheroutre 2005) or “partially activated” (Roberts et al., 1993) have been 
coined. These terms refer mainly to the spontaneous cytotoxicity of CD8+ IEL in ex 
vivo assays.  
   The spontaneous cytotoxicity of human intestinal IEL is directed against several 
cancer cell lines and not against the NK cell-sensitive target cell line K-562 (Roberts 
et al., 1993), but the exact antigenic specificity of these IEL is largely unknown. In the 
murine system studied here, the highly cytotoxic CD8+ IEL harvested from IL-10-/- 
mice specifically lysed TAg-expressing mKSA cells, but not the TAg-negative, 
syngeneic Meth A tumor cells. Moreover, mKSA-specific cytolysis was strictly 
dependent on prior immunization of IL-10-/- mice with TAg, suggesting that the CD8+ 
IEL are specifically reacting to TAg. It appears likely that the generation of TAg-
reactive IEL depends on the intraperitoneal route of immunization with TAg we have 
chosen. Via this route, TAg might get access to the intestine-associated lymphatic 
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tissues, in which IEL are primed against antigens derived from intestinal pathogens, 
as shown previously for the model antigen ovalbumin injected i.p. (Kim et al., 1998).        
   The frequency of TAg-specific CD8+ IEL was found to be in IL-10-/- mice up to  
threefold higher than in wt mice, which appears surprisingly low considering the 
extremely rapid and effective eradication of mKSA cells in IL-10-/- mice and the 
stunning difference in the TAg-specific cytotoxic activity between IL-10-/- and wt CD8+  
IEL. It remains to be investigated in more detail, whether antigen-specific CD8+ IEL 
from IL-10-/- and wt mice differ with regard to the amount or composition of their 
cytotoxic effector molecules. 
   IEL are assumed to be in constant standby mode as a first-line defense against 
enteral pathogens or early intestinal cancer cells. Thus, within the intestinal epithelia 
they are strategically positioned to ward off pathogens invading the epithelia from the 
luminal side or against tumor cells emerging from within the epithelia. Our data 
suggest that CD8+ IEL are also able to respond to invaders approaching from the 
visceral surface of the intestine. The challenging inoculum of mKSA cells is injected 
intraperitoneally and our histologic analyses show micrometastases mainly within the 
peritoneum and occasionally attached to the visceral layers of the intestines. It is 
conceivable that cells of the peritoneum and of the visceral layers of the intestines 
respond to the invasion by mKSA cells by secreting proinflammatory cytokines or 
chemokines that activate and attract IEL from the epithelia to the deeper layers of the 
intestines.  
   A selective homing specificity of TAg-specific CD8+ IEL is suggested by our 
adaptive transfer experiments: CD8+ IEL transferred intravenously fully protect naïve 
wt mice against intraperitoneal challenge with mKSA cells, while the same effector 
cells transferred intraperitoneally do not protect against i.p. inoculated mKSA cells. At 
the first glance this behavior of the IEL appears counter-intuitive, because it might be 
expected that i.p. injection of IEL and mKSA cells into the same compartment should 
accelerate or facilitate the detection and destruction of the tumor cells by the CD8+ 
IEL. However, considering the colonization of the peritoneum and the visceral layers 
of the intestines by mKSA cells, it appears more likely that the decisive encounters 
between tumor cells and IEL take place within the visceral layers of the intestines. 
Access to these sites from the bloodstream appears to resemble the physiologic 
route for IEL on immunosurveillance.     
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    Another important conclusion that can be drawn from the adoptive transfer 
experiments regards the stage at which IL-10 exerts its decisive effect on TAg-
specific CD8+ IEL. The protection of naïve wt mice mediated by adoptively 
transferred CD8+ IEL from IL-10-/- mice indicates that the IL-10-competent milieu in wt 
mice does not impair the effector functions of the IEL. This suggests that IL-10 
secreted either during the immunization phase or during the first 2 days after 
challenge of TAg-immunized mice with mKSA cells impairs the generation of TAg-
specific CD8+ IEL in wt mice.  
   Prime suspects as the source of IL-10 suppressing the generation of TAg-specific 
CD8+ IEL were peritoneal CD4+ T cells secreting large quantities of IL-10 from early 
on after challenge of TAg-immune wt mice with mKSA cells. However, T cell-derived 
IL-10 is not vital in preventing the generation of antigen-specific CD8+ IEL, because 
in TAg-immune mice with a T cell-specific inactivation of the gene coding for IL-10 
neither accelerated rejection of mKSA cells nor enhanced TAg-specific cytotoxicity of 
CD8+ IEL were observed. Likely sources of IL-10 are monocytes, macrophages, and 
dendritic cells. As APC they are involved in priming of antigen-specific IEL. 
Additionally, intestinal epithelial cells are known to secrete IL-10 into the direct 
environment of IEL, which might be important for immune homeostasis in the 
intestine.  
   Taken together, this study demonstrates that tumor antigen-specific, cytotoxic 
CD8+ IEL generated in an IL-10-deficient milieu are able to control highly malignant 
tumor cells with stunning efficacy both in situ and after adoptive transfer into naïve 
hosts.  
 
 
4.III.  Tumorigenicity of murine embryonic stem cells caused by serpin-CI-   
        mediated protection against NK cells 
 
    Embryonic stem cells are pluripotent cells that are capable to differentiate into any 
cell type of the organism. 
The isolation of ES cells from several mammalian species, including humans, raised 
high expectations to apply these cells for the generation of irreversibly damaged 
tissues and organs. ES cells already have been successfully differentiated into 
specific cell types like neurons (Schuldiner et al., 2001; Svendsen et al., 1999), 
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endothelial cells (Levenberg et al., 2002), cardiomyocytes (Kehat et al., 2001), 
hematopoetic precursors (Dang et al., 2002), keratinocytes (Green et al., 2003), 
osteoblasts (Lerou et al., 2005), hepatocytes (Dang et al., 2002) or insulin producing 
pancreatic β cells (Soria et al., 2001). Thus, ES cells represent in principle an 
unlimited source of cells for future approaches in the treatment of hither to non 
curable diseases like spinal cord injury (McDonald et al., 1999), heart failure (Kehat 
et al., 2003), or diabetes mellitus (Axelrod et al., 1983). However, in regenerative 
medicine transplants of ES cells or of ES cell derived grafts faces the same 
immunologic barriers as conventional organ transplants. Remarkably, the 
immunologic implications of ES cell based therapy became only recently a focus of 
interest in regenerative medicine (Bradley et al., 2002). 
To date little is known about the immunologic characteristics of ES cells. For a long 
time, basic assumptions about the interaction of ES cells and effector cells of the 
immune system were just deduced from simple observations. For example it was 
assumed that the observed low or absent lysis of ES cells by antigen-specific CD8+ 
CTL is due to the low surface expression of MHC class I molecules on ES cells. 
However, recently our group revealed that ES cells are fully recognized by antigen-
specific CTL but they evade cytotoxicity by expression of cathepsin B and SPI-6, the 
specific inhibitors of perforin and granzyme B, respectively (Abdullah et al., 2007). 
 
 
4.III.1. ES cells are fully recognized by cytotoxic effector cell but poorly lysed     
           by NK cells     
 
      ES cells were assumed to be immunoprivileged in a recipient organism for at 
least two major reasons (Li et al., 2004; Burt et al., 2004): First, ES cells express 
none or low levels of MHC class I molecules on their surface, so that they might be 
ignored by MHC I restricted cytotoxic T-lymphocytes. Second, ES cells are derived 
from pre-implantation embryos which are usually not rejected by the mothers immune 
system despite being true semiallogeneic implants with half of their proteins being 
foreign paternal antigens (Rukavina et al., 2000). 
Confirming previous studies about the immunologic properties of ES cells, we show 
here that ES cells express none or low levels of MHC class I molecules on their 
surface. According to the „missing self hypothesis“ of NK cell activation (Ljunggren et 
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al., 1990) a major trigger for NK cell mediated cytotoxicity is absent or low level 
expression of MHC class I molecules on cells. Thus, ES cells should be ideal targets 
for NK cells. However, human (Drukker et al., 2002; Drukker et al., 2006; Bonde et 
al., 2006) or murine ES cells (Bonde et al., 2006) were reported to be poorly lysed by 
NK cells in vitro. 
To study the interaction of ES cells and NK cells in detail, we used CGR8 ES cells. In 
contrast to most other ES cell lines, these cells do not depend on feeder cells, which 
avoids any artefacts due to interference of feeder cells in immunologic assays. CGR8 
cells were at least 2-fold less susceptible cells to NK cell mediated lysis than YAC 
cells, which are the standard target cells for murine NK cells. This holds true for 
resting as well as poly I:C induced NK cells. To exclude the possibility that the low 
susceptibility of ES cells to NK cells is due to the activation of NK cells by the non-
physiological stimulus poly I:C, NK cells activated during infection of mice with the 
LCM-virus were used. Undifferentiated ES cells were lysed by LCM-virus induced NK 
cells as by polyI:C activated NK cells, precluding that the reduced level of cytotoxicity 
is due to non-physiologically or sub-optimally activated NK cells.  
Remarkably, contact with either ES cells or YAC cells stimulated resting as well as 
activated NK cells to secrete similar high amounts of IFNγ. This observation indicates 
that ES cells are not ignored by NK cells, but rather fully recognized.  
 
 
4.III.2. Active protection of ES cells against effector cells of the immune    
           system 
 
      This constellation of reduced cytolysis despite full recognition is similar to the 
interaction of ES cells and CTL as reported by us recently (Abdullah et al., 2007). We 
detected in ES cells high amounts of cathepsin B and SPI-6, specific endogenous 
inhibitors of the cytotoxic effector molecules perforin and granzyme B, respectively. 
Knock down of SPI-6 by specific shRNA fully restored susceptibility of murine ES 
cells to lysis by CD8+ CTL. Therefore, involvement of SPI-6 and cathepsin B in the 
low susceptibility of ES cells to NK cells was assessed. By using NK cells from 
perforin deficient mice as effector cells against ES cells, we confirmed that perforin is 
an essential effector molecule in lysis of ES cells by NK cells. Surprisingly, blocking 
the perforin specific inhibitor cathepsin B by CA074 in ES cells did not enhance lysis 
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of ES cells. Interestingly, inhibition of cathepsin B in ES cells by CA074 did also not 
enhance susceptibility of ES cells to perforin-mediated lysis by CTL, as reported by 
us previously (Abdullah et al., 2007). Thus, the biological significance of cathepsin B- 
expression in ES cells remains to be elucidated. 
NK cells and CTL both lyse their target cells mainly by granule mediated effector 
mechanisms. In addition to perforin, granzymes are essential cytotoxic effector 
molecules. Having shown previously that ES cells resist lysis by CTL by expression 
of SPI-6, the specific inhibitor of granzyme B, the hypothesis was tested that SPI-6 
also contributes to the low susceptibility of ES cells for NK cells.  
Knock down of SPI-6 did not increase the susceptibility of ES cells to NK cells, 
although it rendered ES cells fully susceptible to lysis by CTL. Recently, it was 
realized that despite using the common granule mediated cytotoxic pathway, NK 
cells and CTL differ in their repertoire of cytotoxic effector molecules (Smyth et al., 
1995; Sayers et al., 2001; Chowdhury et al., 2008; Janice et al., 2004). A prominent 
difference is the high expression of granzyme M in NK cells. Although the precise 
molecular function of granzyme M has not been elucidated, SPI-CI has been 
identified as its specific inhibitor (Bots et al., 2005). SPI-CI irreversibly interacts with 
purified granzyme M and was shown to protect e.g. tumor cells from granzyme M 
mediated lysis . We detected high levels of SPI-CI mRNA expression in murine ES 
cells. Stable knock down of SPI-CI by lentiviral expression of specific shRNA 
rendered ES cells fully susceptible to lysis not only by activated NK cells, but also by 
resting NK cells. After combined  knock down of both SPI-CI and SPI-6, we did not 
observe an  increased susceptibility of CGR8 ES cells for NK cell mediated lysis. In 
contrast in the colon carcinoma cell line CMT 93 Medema and co-workers observed 
that only combined knock down of SPI-CI and SPI-6 rendered these cells susceptible 
to lysis by activated NK-like cells (Bots et al., 2005).  
These different outcomes of combined knock down of SPI-6 an SPI-CI may either be 
due to different properties of the target cells or differences of the cell populations 
used in the respective studies. 
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4.III.3.  Relevance of SPI-CI  for the survival and tumorigenicity of ES cells in    
           vivo 
 
      After having identified a contribution of constitutively expressed SPI-CI to the low 
susceptibility of ES cells for NK cell mediated cytotoxicity, the relevance of SPI-CI for 
the survival and growth of ES cells was studied in vivo.  
Monitoring the number of i.v. injected fluorescently labeled ES cells homing to the 
spleens of immuno-competent mice revealed a significant effect of the SPI-CI 
expression in ES cells upon the short time survival of these cells in vivo. 
Compared to wild type ES cells five time lower numbers of shSPI-CI ES cells 
accumulated in the spleens of naïve as well as of poly I:C pre-treated wild type 
recipients, within four hours after i.v. injection 
Our hypothesis to explain this differential accumulation of shSPI-CI ES cells versus 
wild type ES cells in the spleens was that shSPI-CI ES cells might be eliminated by 
NK cells more efficiently than wild type ES cells. Another remote explanation for the 
differential accumulation of shSPI-CI ES cells versus wild type ES cells in spleens 
would be altered migration of these cells in vivo. 
To differentiate between these alternatives the fate of i.v. injected ES cells was 
monitored in perforin deficient and in beige mice. Perforin deficient mice and beige 
mice are impaired in NK and CTL mediated cytotoxicity (Baca et al., 1988; Kagi et 
al.,1994; Stinchcombe et al., 2000).In perforin deficient mice as well as in beige mice, 
shSPI-CI ES cells and wild type ES cells accumulated in the spleens to comparable 
numbers. Thus in mice with profound defects in cell mediated cytotoxicity, ES cells 
are not eliminated within four hours, while in fully immuno-competent mice, only 
shSPI-CI ES cells are eliminated. 
In syngeneic 129 OLA/Hsd mice wild type ES cells and ES cells with scr shRNA gave 
rise to palpable teratomas in about eight days after transplantation, that grew within 
27 days to 10 mm in diameter, so that the mice had to be euthanasised. In contrast  
shSPI-CI ES cells developed in only about 50% of the recipients teratomas, and if so, 
the tumors grew very slowly in syngeneic OLA/Hsd mice. 
    These results suggest, that via protection of ES cells against NK cell mediated 
cytotoxicity expression of SPI-CI contributes to the tumorigenicity of ES cells in vivo. 
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6. Abstract  
6.1. Effects of IL-4 and IL-10 on CD8+ CTL in a tumor antigen-specific immune    
       response 
 
    Sustained control or even eradication of tumors by immunotherapy requires 
durable and highly effective tumor-specific CD8+ cytotoxic T lymphocytes (CTL). In 
this report we analyzed the impact of interleukin-4 (IL-4) and interleukin-10 (IL-10) on 
tumor-associated simian virus 40 (SV40) large T-antigen (TAg)-specific CD8+ 
cytotoxic T cells during rejection of syngeneic SV40 transformed mKSA tumor cells in 
BALB/c mice.  
    Strikingly, challenge of naïve mice with low doses of mKSA tumor cells revealed a 
CD8+ T cell-dependent prolonged survival time of naïve IL-4-/- mice. In mice 
immunized with SV40 TAg we observed in IL-4-/- mice, or in wild type mice treated 
with neutralizing anti-IL-4 monoclonal antibody, a strongly enhanced TAg-specific 
cytotoxicity of tumor associated CD8+ T cells. The enhanced cytotoxicity in IL-4-/- 
mice was accompanied by a significant increase in the fraction of CD8+ tumor 
associated T-cells expressing the cytotoxic effector molecules granzyme A and B and 
in granzyme B-specific enzymatic activity. The data suggest that endogenous IL-4 
can suppress the generation of CD8+ CTL expressing cytotoxic effector molecules 
especially when the antigen induces only a very weak CTL response. 
   In IL-10-deficient mice we here describe a previously unrecognized population of 
tumorantigen-specific cytotoxic intraepithelial lymphocytes (IEL) whose anti-tumoral 
effectivity by far exceeds that of conventional CD8+ CTL.  
TAg-immune IL-10-/- BALB/c mice reject intraperitoneal TAg-expressing mKSA tumor 
cells more rapidly than wt mice. TAg-specific conventional CD8+ CTL became 
detectable in the peritoneal exudate of wt mice on day 6 after challenge. 
Unexpectedly, already on day 2 after challenge highly cytotoxic, TAg-specific CD8+ 
small intestinal intraepithelial lymphocytes (IEL) emerged in IL-10-/- mice but not in wt 
mice. When adoptively transferred, only CD8+ IEL from IL-10-/- mice but not 
conventional CD8+ CTL from wt mice, conferred to naïve wt recipients full protection 
against mKSA cells.   
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6.2. Tumorigenicity of murine embryonic stem cells caused by serpin-CI-   
       mediated protection against NK cells 
 
       Undifferentiated human and murine embryonic stem (ES) cells express very low 
to undetectable levels of MHCI molecules. Fulfilling the ‘missing self‘ criterion,  ES 
cells should be readily recognized and lysed by NK cells.  However,  ES cells were 
previously reported to be poorly lysed by NK cells, which was assumed to be due to 
low or missing expression of activating ligands for NK cells.  
Here, we report that murine ES cells were poorly lysed by either resting NK cells or 
activated NK cells although these NK cell populations recognized ES cells and 
secreted IFN-γ in response to target cell contact. 
Murine ES cells express the serine protease inhibitor involved in cytotoxicity inhibition 
(SPI-CI). SPI-CI works as a specific inhibitor of granzyme M, a major component of 
the cytotoxic effector molecules stored in cytotoxic granules of NK cells.  Knock down 
of SPI-CI by stable lentiviral expression of SPI-CI-specific shRNA (ES/shSPI-CI)  
sensitized ES cells for lysis by NK cells. After i.v. injection into syngeneic mice, 
ES/shSPI-CI cells were eliminated from the spleen more effectively than parental wt 
ES cells. ES/shSPI-CI cells implanted s.c. into syngeneic mice developed in only 
about 60% of the recipients very slowly growing tumors, barely detectable at 21 days 
post injection with average diameters below 1mm. This is in stark contrast to wt ES 
cells that gave rise to fast growing teratoma in all recipients with a mean diameter of 
more than 5mm at 21 days post injection.  
Our data suggest that constitutive expression of SPI-CI protects murine ES cells 
against lysis by NK cells in vitro and in vivo and thereby contributes to the 
tumorigenicity of ES cells.   
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6.1. Einfluss von IL-4 und IL-10 auf CD8+ ZTL während der antigenspezifischen    
       Tumor Abstoßung 
 
    Für die Abstoßung von Tumoren sind hoch aktive, tumorspezifische zytotoxische 
CD8+ T-Lymphozyten  (ZTL) unbedingt notwendig. In dieser Arbeit wurde untersucht 
welchen Einfluss Interleukin-4 (IL-4) und Interleukin-10 (IL-10)  auf tumorassoziierte, 
für das große Tumor-Antigen (TAg) des Simian Virus 40 (SV40) spezifische CD8+ T-
Zellen, während der Abstoßung von syngenen SV40 transformierten mKSA 
Tumorzellen, in BALB/c Mäusen haben. 
   Erstaunlicherweise führte die Belastung mit wenig Tumorzellen bei naiven IL-4-/- 
Mäusen, im Vergleich zu Wildtyp Mäusen, zu einer verlängerten, CD8+ T-Zell 
abhängigen Überlebenszeit. Bei mit SV40 TAg immunisierten IL-4-/- oder bei mit  
monoklonalem anti-IL-4 Antikörper behandelten Mäusen wurde eine stark erhöhte 
TAg-spezifische Zytotoxizität von tumorassoziierten CD8+ T-Zellen beobachtet. Diese 
gesteigerte Zytotoxizität in IL-4-/- Mäusen ging mit einem signifikant erhöhten Anteil 
von Granzyme A und B, und einer erhöhten spezifischen Aktivität von Granzyme B, 
in den tumorassoziierten CD8+ T-Zellen einher. 
Somit kann IL-4 die Generierung zytotoxischer Effektor Moleküle in CD8+ ZTL 
behindern, vor allem wenn eine eher schwache Immunantwort durch das Antigen 
hervorgerufen wird. 
   In Interleukin (IL-) 10-defizienten Mäusen haben wir eine neue Population  
tumorantigenspezifischer, intraepithelialer Lymphozyten identifiziert. Diese 
zytotoxischen, CD8+ intestinalen intraepithelialen Lymphozyten (IEL) können 
wesentlich effektiver als konventionelle CD8+ zytotoxische T-Lymphozyten (CTL) 
Tumorzellen eliminieren. TAg-immune IL-10-/- BALB/c stoßen mKSA Tumorzellen, 
die das große Tumorantigen des SV 40 Virus exprimieren, schneller ab als WT 
Mäuse. In WT Mäusen sind 6 Tage nach Tumorbelastung TAg-spezifische 
konventionelle CD8+ CTL in der Peritonealhöhle nachweisbar. Erstaunlicherweise 
konnten aus IL-10-/- Mäusen, aber nicht aus Wildtyp Mäusen,  schon 2 Tage  nach 
Tumorbelastung TAg-spezifische CD8+ intestinale intraepitheliale Lymphozyten 
isoliert werden. Während durch konventionelle T-Zellen kein Schutz vermittelt werden 
konnte, wurden naive Empfänger im adoptiven Transfer durch CD8+ IEL, von IL-10 -/- 
Mäusen, vollständig geschützt.  
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6.2. Die Expression von SPI-CI schützt ES Zellen zum Teil vor NK Zellen und   
       trägt zu der Bildung von Teratomen bei 
 
    Undifferenzierte humane und murine embryonale Stammzellen (ES Zellen) 
exprimieren nur sehr wenig oder keine MHC Klasse I Moleküle auf der Oberfläche. 
Somit erfüllen ES Zellen, der „missing self Hypothese“ zufolge, alle 
Vorraussetzungen als ideale Zielzellen für NK Zellen. Allerdings wurde bisher 
gezeigt, dass ES Zellen nur sehr schlecht von NK Zellen lysiert werden. Als Grund 
für die schlechte Lyse von ES Zellen durch NK Zellen wurde die geringe Expression 
von aktivierenden Liganden für NK Zellen auf ES Zellen vermutet. 
In dieser Arbeit zeigen wir, dass ES Zellen trotz der Tatsache, dass die verwendeten 
NK-Zellpopulationen ES Zellen gut erkennen und nach Kontakt große Mengen von 
IFNγ sezernieren, nur gering von ruhenden und aktivierten NK Zellen lysiert werden. 
Murine ES Zellen exprimieren den Serin Protease Inhibitor SPI-CI, den spezifischen 
Inhibitor von Granzyme M. Granzyme M wiederum ist ein wichtiger Bestandteil der 
zytotoxischen Effektormoleküle, gespeichert in den zytotoxischen Granular von NK 
Zellen.  
Durch stabile Hemmung von SPI-CI, mit Hilfe von einem spezifisch für SPI-CI 
exprimierenden shRNA Vector (ES/shSPI-CI), konnte das Lyse-Niveau von ES 
Zellen durch  ruhende oder aktivierte NK Zellen angehoben werden.  
Nach intravenöser Injektion in syngene Mäuse wurden die shSPI-CI Zellen 
bedeutend besser als die Wildtyp ES Zellen aus der Milz eliminiert. 
Auch nach subkutaner Injektion der shSPI-CI Zellen in syngene Mäuse konnte nur 
bei 60% der Empfänger, an Tag 21 nach Injektion, ein Tumor unter 1mm festgestellt 
werden. Im Gegensatz dazu entstanden aus subkutan implantierten Wildtyp ES 
Zellen in allen Empfängern schnell wachsende Tumore, mit einem durchschnittlichen 
Durchmesser von 21mm. 
   Die konstitutive Expression von SPI-CI schützt somit ES Zellen, in vitro und in vivo, 
vor der Lyse durch NK Zellen und trägt letztlich zu ihrer Tumorigenität bei. 
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